<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Anxiolytic</title><meta name="description" content="An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="anxiolytics, anti-anxiety drug, anti-anxiety medication, minor tranquilizer"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Anxiolytic"/><meta property="og:title" content="Anxiolytic"/><meta property="og:description" content="An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear..."/><meta property="og:url" content="https://grokipedia.com/page/Anxiolytic"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Anxiolytic"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.399Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Anxiolytic"/><meta name="twitter:description" content="An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="d9ddea04a64978bd53cabe5897e51cc4-ff2831c4b749cc19-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=d9ddea04a64978bd53cabe5897e51cc4,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.41123171775276957,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>⌘</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#anxiolytic" class="transition-opacity hover:opacity-100 opacity-50">Anxiolytic</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#nature-of-anxiety" class="transition-opacity hover:opacity-100 opacity-50">Nature of Anxiety</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#etiology" class="transition-opacity hover:opacity-100 opacity-50">Etiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medications" class="transition-opacity hover:opacity-100 opacity-50">Medications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classifications" class="transition-opacity hover:opacity-100 opacity-50">Classifications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antidepressants" class="transition-opacity hover:opacity-100 opacity-50">Antidepressants</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#benzodiazepines" class="transition-opacity hover:opacity-100 opacity-50">Benzodiazepines</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#azapirones" class="transition-opacity hover:opacity-100 opacity-50">Azapirones</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antiepileptics" class="transition-opacity hover:opacity-100 opacity-50">Antiepileptics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antipsychotics" class="transition-opacity hover:opacity-100 opacity-50">Antipsychotics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#beta-adrenoceptor-antagonists" class="transition-opacity hover:opacity-100 opacity-50">Beta-adrenoceptor antagonists</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-of-action" class="transition-opacity hover:opacity-100 opacity-50">Mechanism of action</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ssris-and-snris" class="transition-opacity hover:opacity-100 opacity-50">SSRIs and SNRIs</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#benzodiazepine" class="transition-opacity hover:opacity-100 opacity-50">Benzodiazepine</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-use" class="transition-opacity hover:opacity-100 opacity-50">Clinical use</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#selective-serotonin-reuptake-inhibitors" class="transition-opacity hover:opacity-100 opacity-50">Selective serotonin reuptake inhibitors</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-use" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic use</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effect" class="transition-opacity hover:opacity-100 opacity-50">Adverse effect</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#serotoninnorepinephrine-reuptake-inhibitors" class="transition-opacity hover:opacity-100 opacity-50">Serotonin–norepinephrine reuptake inhibitors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#tricyclic-antidepressants" class="transition-opacity hover:opacity-100 opacity-50">Tricyclic antidepressants</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-use-1" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic use</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#contraindication" class="transition-opacity hover:opacity-100 opacity-50">Contraindication</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#tetracyclic-antidepressants" class="transition-opacity hover:opacity-100 opacity-50">Tetracyclic antidepressants</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#monoamine-oxidase-inhibitors" class="transition-opacity hover:opacity-100 opacity-50">Monoamine oxidase inhibitors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#barbiturates" class="transition-opacity hover:opacity-100 opacity-50">Barbiturates</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#benzodiazepines-1" class="transition-opacity hover:opacity-100 opacity-50">Benzodiazepines</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-use-2" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic use</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effect-1" class="transition-opacity hover:opacity-100 opacity-50">Adverse effect</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#sympatholytics" class="transition-opacity hover:opacity-100 opacity-50">Sympatholytics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#miscellaneous" class="transition-opacity hover:opacity-100 opacity-50">Miscellaneous</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#buspirone" class="transition-opacity hover:opacity-100 opacity-50">Buspirone</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pregabalin" class="transition-opacity hover:opacity-100 opacity-50">Pregabalin</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hydroxyzine" class="transition-opacity hover:opacity-100 opacity-50">Hydroxyzine</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#phenibut" class="transition-opacity hover:opacity-100 opacity-50">Phenibut</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#temgicoluril" class="transition-opacity hover:opacity-100 opacity-50">Temgicoluril</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fabomotizole" class="transition-opacity hover:opacity-100 opacity-50">Fabomotizole</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#bromantane" class="transition-opacity hover:opacity-100 opacity-50">Bromantane</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emoxypine" class="transition-opacity hover:opacity-100 opacity-50">Emoxypine</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#menthyl-isovalerate" class="transition-opacity hover:opacity-100 opacity-50">Menthyl isovalerate</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#racetams" class="transition-opacity hover:opacity-100 opacity-50">Racetams</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#alpidem" class="transition-opacity hover:opacity-100 opacity-50">Alpidem</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#etifoxine" class="transition-opacity hover:opacity-100 opacity-50">Etifoxine</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#alcohol" class="transition-opacity hover:opacity-100 opacity-50">Alcohol</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#alternatives-to-medication" class="transition-opacity hover:opacity-100 opacity-50">Alternatives to medication</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="anxiolytic" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Anxiolytic<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">An <strong>anxiolytic</strong> (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also <strong>anti-anxiety agent</strong>)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.</span>
<h1 id="nature-of-anxiety" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Nature of Anxiety<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, <span class="inline text-[1em] leading-7">anxiety disorders</span> may occur. People with anxiety disorders can exhibit fear responses, such as defensive behaviors, high levels of alertness, and <span class="inline text-[1em] leading-7">negative emotions</span>. Those with anxiety disorders may have concurrent psychological disorders, such as <span class="inline text-[1em] leading-7">depression</span>. Anxiety disorders are classified according to criteria in the DSM-5.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Common types include:</span>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Type</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Description</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Generalized anxiety disorder (GAD)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">The anxiety symptoms are usually persistent and constant. Patients of this disorder could experience excessive anxiety for a long duration, commonly over six months and the symptoms could occur without any specific triggers.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Panic disorder</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">This disorder specifically refers to the suffering from panic attacks and also the fear of repetitive attacks. It is often associated with agoraphobia (the fear of situations where escape might be difficult). Panic attacks are sudden upsurges in anxiety level usually with unexplained reasons.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Social anxiety disorder</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">This refers to the fear of engaging in social situations where one experiences public observation among people or performs in front of the public. The fears are often unexplained and persistent. The fear could also be attributed to the possible humiliation in front of others due to poor performance or awkward social interactions.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Specific phobias</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Persistent fear towards a specific object, either tangible or intangible. This leads to undeniable avoidance or thought of escape from the object or endurance of the object in immense levels of anxiety.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Agoraphobia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Intense fear or anxiety triggered by exposure to situations where escape might be difficult or help unavailable, such as open spaces, crowds, or public transportation. Often leads to avoidance behaviors.</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Separation anxiety disorder</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Excessive fear or anxiety concerning separation from home or attachment figures, inappropriate for the individual&#x27;s developmental level. Symptoms include distress when anticipating or experiencing separation.</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Different types of anxiety disorders will share some general symptoms while having their own distinctive symptoms. This explains why people with different types of anxiety disorders will respond differently to different classes of anti-anxiety medications.</span>
<h1 id="etiology" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Etiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The etiology of anxiety disorders is multifactorial and involves an interaction of genetic vulnerability with environmental and psychological factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Risk factors include a family history of anxiety disorders, traumatic or stressful life events, adverse childhood experiences, certain medical conditions such as metabolic or endocrine disorders (e.g., hyperthyroidism, diabetes), substance use or withdrawal including central nervous system stimulants, and comorbid psychiatric conditions like depression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="medications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Medications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Anti-anxiety medication is any drug that can be taken or prescribed for the treatment of anxiety disorders, which may be mediated by neurotransmitters like norepinephrine, serotonin, dopamine, and gamma-aminobutyric acid (GABA) in the central nervous system.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Anti-anxiety medication can be classified into six types according to their different mechanisms: antidepressants, benzodiazepines, azapirones, antiepileptics, antipsychotics, and beta blockers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs and SNRIs are both used as first-line treatments across various anxiety disorders, including generalized anxiety disorder (GAD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> TCAs are second-line treatment as they cause more significant adverse effects when compared to the first-line treatment. Benzodiazepines are effective in emergent and short-term treatment of anxiety disorders due to their fast onset but carry the risk of dependence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Buspirone is indicated for GAD, which has much slower onset but with the advantage of less sedating and withdrawal effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The use of anxiolytics dates back to the 19th century with sedatives like bromides and chloral hydrate. Barbiturates, introduced in 1903 with barbital, became the first widely used class for treating anxiety and insomnia, though they carried high risks of dependence and overdose.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the 1950s, non-barbiturate sedatives emerged, including meprobamate (approved 1955), which was marketed as a safer alternative for anxiety. The benzodiazepine class revolutionized anxiolytic treatment when chlordiazepoxide (Librium) was synthesized in 1955 and approved in 1960, followed by diazepam (Valium) in 1963. These agents targeted the GABA_A receptor, providing effective anxiety relief with lower toxicity than barbiturates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup>; <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The first monoamine oxidase inhibitor (MAOI), iproniazid, was discovered accidentally in 1951 while developing the antitubercular drug isoniazid. It was found to induce euphoria and improve patients&#x27; appetite and sleep quality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The first tricyclic antidepressant (TCA), imipramine, was originally developed and studied as an antihistamine alongside other first-generation antihistamines of the time, such as promethazine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> TCAs increase the levels of norepinephrine and serotonin by inhibiting their reuptake transport proteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Many TCAs also have significant anticholinergic and antihistaminergic properties, leading to side effects like drowsiness and memory loss.</span>
<span class="mb-4 block break-words text-[1em] leading-7">To achieve greater selectivity for serotonin reuptake inhibition and avoid anticholinergic and antihistaminergic side effects, selective serotonin reuptake inhibitors (SSRIs) were developed. The first SSRI, fluoxetine (Prozac), was synthesized in 1972, patented in 1974, and approved by the FDA in 1987 for depression; it was later used for anxiety disorders. Subsequently, other SSRIs such as sertraline (Zoloft, approved 1991), paroxetine (Paxil, approved 1992), and escitalopram (Lexapro, approved 2002) entered the market.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup>;</span>
<span class="mb-4 block break-words text-[1em] leading-7">The first serotonin-norepinephrine reuptake inhibitor (SNRI), venlafaxine (Effexor), was approved for depression in 1993 and later for anxiety.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> SNRIs target serotonin and norepinephrine transporters while having minimal effects on other adrenergic (α1, α2, and β), histamine (H1), muscarinic, dopamine, or postsynaptic serotonin receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h1 id="classifications" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Classifications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">There are six groups of anti-anxiety medications available that have been proven to be clinically significant in treatment of anxiety disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> The groups of medications are as follows.</span>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Drug Class</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Examples</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Antidepressants</span><span class="text-[1em] leading-7"> (e.g., SSRIs, SNRIs)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">SSRIs e.g., fluoxetine, sertraline; SNRIs e.g., venlafaxine; MAOIs; TCAs</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Benzodiazepines</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lorazepam, diazepam, alprazolam</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Azapirones</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Buspirone, gepirone, tandospirone</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Antiepileptics</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Gabapentin, pregabalin, tiagabine and valproate</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Antipsychotics</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Olanzapine, risperidone</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Beta-adrenoceptor antagonists</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Propranolol, atenolol</span></td></tr></tbody></table></div>
<h3 id="antidepressants" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antidepressants<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Medications that are indicated for both anxiety disorders and depression. <span class="inline text-[1em] leading-7">Selective serotonin reuptake inhibitors</span> (SSRIs) and <span class="inline text-[1em] leading-7">serotonin–norepinephrine reuptake inhibitors</span> (SNRIs) are new generations of antidepressants. They have a much lower adverse effect profile than older antidepressants like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Therefore, SSRIs and SNRIs are now the first-line agent in treating long term anxiety disorders, given their applications and significance in all six types of disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="benzodiazepines" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Benzodiazepines<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Benzodiazepines</span> are used for acute anxiety and could be added along with current use of SSRIs to stabilize a treatment. Long-term use in treatment plans is not recommended. Different kinds of benzodiazepine will vary in its pharmacological profile, including its strength of effect and time taken for metabolism. The choice of the benzodiazepine will depend on the corresponding profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Benzodiazepines are used for emergent or short-term management. They are not recommended as the first-line anti-anxiety drugs, but they can be used in combination with SSRIs/SNRIs during the initial treatment stage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Indications include panic disorder, sleep disorders, seizures, acute behavioral disturbance, muscle spasm and premedication and sedation for procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="azapirones" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Azapirones<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Buspirone</span> can be useful in GAD but not particularly effective in treating phobias, panic disorder or social anxiety disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> It is a safer option for long-term use as it does not cause dependence like benzodiazepines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="antiepileptics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antiepileptics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Antiepileptics are rarely prescribed as an off-label treatment for anxiety disorders and post-traumatic stress disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> There have been some suggestions that they may help with anxiety symptoms but there is generally a lack of research on its use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">One antiepileptic, <span class="inline text-[1em] leading-7">pregabalin</span>, has been found to be better at treating GAD than a placebo, and comparable effects to benzodiazepines. It has also been shown be potentially efficient in treating social anxiety disorder. <span class="inline text-[1em] leading-7">Gabapentin</span> has been prescribed off-label for anxiety despite a lack of research evidence supporting such use, although some studies have indicated that it may relieve anxiety symptoms. The potential anxiolytic effect of <span class="inline text-[1em] leading-7">tiagabine</span> has been observed in some pre-clinical trials, but its effectiveness has not yet been proved. Similarly, there is a lack of research on <span class="inline text-[1em] leading-7">valproate</span> for the treatment of anxiety disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="antipsychotics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antipsychotics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Olanzapine</span> and <span class="inline text-[1em] leading-7">risperidone</span> are atypical antipsychotics which are also effective in GAD and PTSD treatment. However, there is a higher chance of experiencing adverse effects than the other anti-anxiety medications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="beta-adrenoceptor-antagonists" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Beta-adrenoceptor antagonists<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Propranolol</span> is originally used for high blood pressure and heart diseases. It can also be used to treat anxiety with symptoms like tremor or increased heart rate. They work on the nervous system and alleviate the symptoms as a relief.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Propranolol is also commonly used for public speaking when one is nervous.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h2 id="mechanism-of-action" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Mechanism of action<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="ssris-and-snris" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">SSRIs and SNRIs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) inhibit the reuptake of serotonin (and norepinephrine for SNRIs) by blocking their respective transporters on presynaptic neurons, thereby increasing the concentration of these neurotransmitters in the synaptic cleft and enhancing postsynaptic signaling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> While the precise mechanisms underlying their anxiolytic effects are not fully understood, they are thought to involve adaptive changes in serotonergic (and noradrenergic) systems, such as desensitization of presynaptic 5-HT1A autoreceptors, which initially limit serotonin release but, over time (typically 4–6 weeks), allow for sustained enhancement of transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="benzodiazepine" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Benzodiazepine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Benzodiazepines bind selectively to the <span class="inline text-[1em] leading-7">GABA receptor</span>, which is the receptor protein found in the nervous system and is in control of the nervous response. Benzodiazepine will increase the entry of chloride ions into the cells by improving the binding between <span class="inline text-[1em] leading-7">GABA</span> and GABA receptors and then the better opening of the channel for chloride ion passage. The high level of chloride ion inside the nerve cells makes the nerve more difficult to <span class="inline text-[1em] leading-7">depolarize</span> and inhibit further nerve signal transduction. The excitability of the nerves then reduces and the nervous system slows down. Therefore, the drug can alleviate symptoms of anxiety disorder and make the person less nervous.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h2 id="clinical-use" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="selective-serotonin-reuptake-inhibitors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Selective serotonin reuptake inhibitors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Selective serotonin reuptake inhibitors</span> (SSRIs) are a class of medications used in the treatment of <span class="inline text-[1em] leading-7">depression</span>, <span class="inline text-[1em] leading-7">anxiety disorders</span>, <span class="inline text-[1em] leading-7">OCD</span> and some <span class="inline text-[1em] leading-7">personality disorders</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_olqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> SSRIs are the first-line anti-anxiety medications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_slqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> As of 2025, SSRIs remain first-line per major guidelines (e.g., APA, NICE).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Serotonin is one of the crucial neurotransmitters in mood enhancement, and increasing serotonin level produces an anti-anxiety effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> SSRIs increase the serotonin level in the brain by inhibiting serotonin uptake pumps on serotonergic systems, without interactions with other receptors and ion channels. SSRIs are beneficial in both acute response and long-term maintenance treatment for both depression and anxiety disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">SSRIs can increase anxiety initially due to negative feedback through the serotonergic <span class="inline text-[1em] leading-7">autoreceptors</span>; for this reason a concurrent benzodiazepine can be used until the anxiolytic effect of the SSRI occurs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The SSRIs <span class="inline text-[1em] leading-7">paroxetine</span> and <span class="inline text-[1em] leading-7">escitalopram</span> are <span class="inline text-[1em] leading-7">USFDA</span> approved to treat generalized anxiety disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h4 id="therapeutic-use" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Therapeutic use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>

























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Drug</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Common side effect</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Citalopram</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Depressive illness</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><br/><span class="text-[1em] leading-7">Panic disorder</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mcnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Apathy (caused by decrease in dopamine release)</span><br/><span class="text-[1em] leading-7">Flatulence</span><br/><span class="text-[1em] leading-7">Drowsiness</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_rcnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><br/><span class="inline text-[1em] leading-7">Migraine</span><br/><span class="inline text-[1em] leading-7">Rhinitis</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Escitalopram</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9knqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><span class="text-[1em] leading-7"> (active enantiomer of citalopram)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Depressive illness</span><br/><span class="text-[1em] leading-7">Generalized anxiety disorder</span><br/><span class="text-[1em] leading-7">Obsessive-compulsive disorder</span><br/><span class="text-[1em] leading-7">Panic disorder</span><br/><span class="text-[1em] leading-7">Social anxiety disorder</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Sinusitis</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Fluoxetine</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9snqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Major depression</span><br/><span class="inline text-[1em] leading-7">Bulimia nervosa</span><br/><span class="text-[1em] leading-7">Obsessive-compulsive disorder</span><br/><span class="text-[1em] leading-7">Menopausal symptoms</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Chills</span><br/><span class="text-[1em] leading-7">Feeling abnormal</span><br/><span class="text-[1em] leading-7">Postmenopausal </span><span class="inline text-[1em] leading-7">hemorrhage</span><br/><span class="text-[1em] leading-7">Uterine disorder</span><br/><span class="text-[1em] leading-7">Vasodilation</span><br/><span class="text-[1em] leading-7">Blurred vision</span></td></tr></tbody></table></div>
<h4 id="adverse-effect" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Adverse effect<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">The common early side effects of SSRIs include nausea and loose stool, which can be solved by discontinuing the treatment. Headache, dizziness, insomnia are the common early side effects as well.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Sexual dysfunction</span>, <span class="inline text-[1em] leading-7">anorgasmia</span>, <span class="inline text-[1em] leading-7">erectile dysfunction</span>, and <span class="inline text-[1em] leading-7">reduced libido</span> are common adverse side effects of SSRIs. Sometimes they <span class="inline text-[1em] leading-7">may persist after the cessation of treatment</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Withdrawal symptoms</span> like dizziness, headache and flu-like symptoms (fatigue/myalgia/loose stool) may occur if SSRI is stopped suddenly. The brain is incapable of upregulating the receptors to sufficient levels especially after discontinuation of the drugs with short half-life like paroxetine. Both fluoxetine and its active metabolite have a long half-life therefore it causes the least withdrawal symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<h3 id="serotoninnorepinephrine-reuptake-inhibitors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Serotonin–norepinephrine reuptake inhibitors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Serotonin–norepinephrine reuptake inhibitor</span> (SNRIs) include <span class="inline text-[1em] leading-7">venlafaxine</span> and <span class="inline text-[1em] leading-7">duloxetine</span> drugs. Venlafaxine, in <span class="inline text-[1em] leading-7">extended release</span> form, and duloxetine, are indicated for the treatment of <span class="inline text-[1em] leading-7">GAD</span>. SNRIs are as effective as SSRIs in the treatment of anxiety disorders.</span>
<h3 id="tricyclic-antidepressants" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Tricyclic antidepressants<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Tricyclic antidepressants</span> (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. They are considered effective, but have generally been replaced by antidepressants that cause different adverse effects. Examples include <span class="inline text-[1em] leading-7">imipramine</span>, <span class="inline text-[1em] leading-7">doxepin</span>, <span class="inline text-[1em] leading-7">amitriptyline</span>, <span class="inline text-[1em] leading-7">nortriptyline</span> and <span class="inline text-[1em] leading-7">desipramine</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_srqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<h4 id="therapeutic-use-1" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Therapeutic use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>




















<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Drugs</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Common side effect</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Imipramine</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Nocturnal </span><span class="inline text-[1em] leading-7">enuresis</span><span class="text-[1em] leading-7"> for children above six years old</span><br/><span class="text-[1em] leading-7">Severe depression</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Antihistamine side effects like sedation, weight gain</span><br/><span class="text-[1em] leading-7">Anticholinergic side effects like blurred vision, dry mouth, constipation</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Clomipramine</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9ksqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Depressive illness</span><br/><span class="text-[1em] leading-7">Phobic and obsessional states</span><br/><span class="text-[1em] leading-7">Adjunctive treatment of </span><span class="inline text-[1em] leading-7">cataplexy</span><span class="text-[1em] leading-7"> associated with </span><span class="inline text-[1em] leading-7">narcolepsy</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="inline text-[1em] leading-7">Arrhythmias</span><br/><span class="text-[1em] leading-7">Breast enlargement</span><br/><span class="text-[1em] leading-7">Dry mouth</span><br/><span class="text-[1em] leading-7">Constipation</span><br/><span class="text-[1em] leading-7">Drowsiness</span><br/><span class="text-[1em] leading-7">Dizziness</span></td></tr></tbody></table></div>
<h4 id="contraindication" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Contraindication<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">TCAs are contraindicated in patients with <span class="inline text-[1em] leading-7">hypotension</span>, cardiovascular diseases and arrhythmias due to risk of toxicity and exacerbation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<h3 id="tetracyclic-antidepressants" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Tetracyclic antidepressants<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Mirtazapine</span> has demonstrated anxiolytic effect comparable to SSRIs while rarely causing or exacerbating anxiety. Mirtazapine&#x27;s anxiety reduction tends to occur significantly faster than SSRIs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h3 id="monoamine-oxidase-inhibitors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Monoamine oxidase inhibitors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Monoamine oxidase inhibitors</span> (MAOIs) are first-generation antidepressants effective for anxiety treatment but their dietary restrictions, adverse effect profile and availability of newer medications have limited their use. MAOIs include <span class="inline text-[1em] leading-7">phenelzine</span>, <span class="inline text-[1em] leading-7">isocarboxazid</span> and <span class="inline text-[1em] leading-7">tranylcypromine</span>. <span class="inline text-[1em] leading-7">Pirlindole</span> is a reversible MAOI that lacks dietary restriction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h3 id="barbiturates" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Barbiturates<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Barbiturates</span> are powerful anxiolytics but the risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<h3 id="benzodiazepines-1" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Benzodiazepines<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Benzodiazepines</span> are prescribed to quell <span class="inline text-[1em] leading-7">panic attacks</span>. Benzodiazepines are also prescribed in tandem with an antidepressant for the latent period of efficacy associated with many ADs for anxiety disorder. There is risk of <span class="inline text-[1em] leading-7">benzodiazepine withdrawal</span> and <span class="inline text-[1em] leading-7">rebound syndrome</span> if BZDs are rapidly discontinued.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Tolerance and dependence may occur.<!-- --> The risk of abuse in this class of medication is smaller than in that of barbiturates. Cognitive and behavioral adverse effects are possible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Benzodiazepines include: <span class="inline text-[1em] leading-7">alprazolam</span> (Xanax), <span class="inline text-[1em] leading-7">bromazepam</span>, <span class="inline text-[1em] leading-7">chlordiazepoxide</span> (Librium), <span class="inline text-[1em] leading-7">clonazepam</span> (Klonopin), <span class="inline text-[1em] leading-7">diazepam</span> (Valium), <span class="inline text-[1em] leading-7">lorazepam</span> (Ativan), <span class="inline text-[1em] leading-7">oxazepam</span>, <span class="inline text-[1em] leading-7">temazepam</span>, and <span class="inline text-[1em] leading-7">Triazolam</span>.</span>
<h4 id="therapeutic-use-2" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Therapeutic use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>

























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Drug</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Common side effect</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lorazepam</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Short term use in anxiety</span><br/><span class="text-[1em] leading-7">Short term use in insomnia associated anxiety</span><br/><span class="inline text-[1em] leading-7">Conscious sedation</span><span class="text-[1em] leading-7"> for procedures</span><br/><span class="text-[1em] leading-7">Premedication</span><br/><span class="inline text-[1em] leading-7">Status epilepticus/febrile convulsions/convulsions</span><span class="text-[1em] leading-7"> caused by poisoning</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Decreased alertness</span><br/><span class="inline text-[1em] leading-7">Ataxia</span><span class="text-[1em] leading-7">, confusion (more in elderly)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Diazepam</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Muscle spasm of varied aetiology</span><br/><span class="text-[1em] leading-7">Anxiety</span><br/><span class="text-[1em] leading-7">Acute drug-induced dystonic reactions</span><br/><span class="text-[1em] leading-7">Sedation for minor surgical and medical procedures</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Abnormal appetite</span><br/><span class="text-[1em] leading-7">Concentration impairment</span><br/><span class="text-[1em] leading-7">Gastrointestinal disorder</span><br/><span class="text-[1em] leading-7">Movement disorder</span><br/><span class="text-[1em] leading-7">Muscle spasm</span><br/><span class="text-[1em] leading-7">Vomiting</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Alprazolam</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Short term use in anxiety</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Poor balance or coordination</span><br/><span class="text-[1em] leading-7">Changes in speech patterns</span><br/><span class="text-[1em] leading-7">Decreased alertness</span><br/><span class="text-[1em] leading-7">Irritability</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_13t3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></td></tr></tbody></table></div>
<h4 id="adverse-effect-1" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Adverse effect<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Benzodiazepines lead to <span class="inline text-[1em] leading-7">central nervous system depression</span>, resulting in common adverse effects like drowsiness, oversedation, light-headedness. Memory impairment can be a common adverse effect especially in elderly, hypersalivation, ataxia, slurred speech, psychomotor effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="sympatholytics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Sympatholytics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Sympatholytics</span> are a group of anti-hypertensives which inhibit activity of the <span class="inline text-[1em] leading-7">sympathetic nervous system</span>. <span class="inline text-[1em] leading-7">Beta blockers</span> reduce anxiety by decreasing heart rate and preventing shaking. Beta blockers include <span class="inline text-[1em] leading-7">propranolol</span>, <span class="inline text-[1em] leading-7">oxprenolol</span>, and <span class="inline text-[1em] leading-7">metoprolol</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> The alpha-1 antagonist <span class="inline text-[1em] leading-7">prazosin</span> could be effective for PTSD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_155abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> The alpha-2 agonists <span class="inline text-[1em] leading-7">clonidine</span> and <span class="inline text-[1em] leading-7">guanfacine</span> have demonstrated both anxiolytic and anxiogenic effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1h5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<h3 id="miscellaneous" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Miscellaneous<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<h4 id="buspirone" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Buspirone<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Buspirone</span> (Buspar) is a <span class="inline text-[1em] leading-7">5-HT1A receptor</span> <span class="inline text-[1em] leading-7">agonist</span> used to treated generalized anxiety disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> If an individual has only recently stopped taking benzodiazepines, buspirone will be less effective.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h4 id="pregabalin" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Pregabalin<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Pregabalin</span> (Lyrica) produces anxiolytic effect after one week of use comparable to <span class="inline text-[1em] leading-7">lorazepam</span>, <span class="inline text-[1em] leading-7">alprazolam</span>, and <span class="inline text-[1em] leading-7">venlafaxine</span> with more consistent psychic and somatic anxiety reduction. Unlike BZDs, it does not disrupt <span class="inline text-[1em] leading-7">sleep architecture</span> nor does it cause cognitive or psychomotor impairment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<h4 id="hydroxyzine" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Hydroxyzine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Hydroxyzine</span> (Atarax) is an <span class="inline text-[1em] leading-7">antihistamine</span> originally approved for clinical use by the FDA in 1956. Hydroxyzine has a calming effect which helps ameliorate anxiety. Hydroxyzine efficacy is comparable to benzodiazepines in the treatment of <span class="inline text-[1em] leading-7">generalized anxiety disorder</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<h4 id="phenibut" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Phenibut<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Phenibut</span> (Anvifen, Fenibut, Noofen) is an anxiolytic<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> used in Russia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Phenibut is a <span class="inline text-[1em] leading-7">GABAB receptor</span> <span class="inline text-[1em] leading-7">agonist</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> as well as an antagonist at <span class="inline text-[1em] leading-7">α2δ subunit</span>-containing <span class="inline text-[1em] leading-7">voltage-dependent calcium channels</span> (VDCCs), similarly to <span class="inline text-[1em] leading-7">gabapentinoids</span> like <span class="inline text-[1em] leading-7">gabapentin</span> and <span class="inline text-[1em] leading-7">pregabalin</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1f9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> The medication is not approved by the FDA for use in the United States, but is sold online as a supplement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1j9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1l9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<h4 id="temgicoluril" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Temgicoluril<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Temgicoluril</span> (Mebicar) is an anxiolytic produced in <span class="inline text-[1em] leading-7">Latvia</span> and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the <span class="inline text-[1em] leading-7">hypothalamus</span>, as well as on all four basic neuromediator systems – <span class="inline text-[1em] leading-7">γ aminobutyric acid</span> (GABA), <span class="inline text-[1em] leading-7">choline</span>, <span class="inline text-[1em] leading-7">serotonin</span> and adrenergic activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_raqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_vaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup></span>
<h4 id="fabomotizole" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Fabomotizole<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Fabomotizole</span> (Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. Its mechanism of action is poorly defined, with GABAergic, <span class="inline text-[1em] leading-7">NGF</span> and <span class="inline text-[1em] leading-7">BDNF</span> release promoting, <span class="inline text-[1em] leading-7">MT1 receptor</span> agonism, MT3 receptor antagonism, and <span class="inline text-[1em] leading-7">sigma receptor</span> agonism thought to have some involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_nbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<h4 id="bromantane" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Bromantane<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Bromantane</span> is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s. Bromantane acts mainly by facilitating the biosynthesis of dopamine, through indirect genomic upregulation of relevant enzymes (<span class="inline text-[1em] leading-7">tyrosine hydroxylase</span> (TH) and <span class="inline text-[1em] leading-7">aromatic L-amino acid decarboxylase</span> (AAAD)).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<h4 id="emoxypine" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Emoxypine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Emoxypine</span> is an <span class="inline text-[1em] leading-7">antioxidant</span> that is also a purported anxiolytic.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Its chemical structure resembles that of <span class="inline text-[1em] leading-7">pyridoxine</span>, a form of vitamin B6.</span>
<h4 id="menthyl-isovalerate" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Menthyl isovalerate<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Menthyl isovalerate</span> is a flavoring food additive marketed as a <span class="inline text-[1em] leading-7">sedative</span> and anxiolytic drug in Russia under the name <em>Validol</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_feqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<h4 id="racetams" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Racetams<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7">Some <span class="inline text-[1em] leading-7">racetam</span> based drugs such as <span class="inline text-[1em] leading-7">aniracetam</span> can have an antianxiety effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<h4 id="alpidem" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Alpidem<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Alpidem</span> is a <span class="inline text-[1em] leading-7">nonbenzodiazepine</span> anxiolytic with similar anxiolytic effectiveness as benzodiazepines but reduced <span class="inline text-[1em] leading-7">sedation</span> and cognitive, memory, and motor impairment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> It was marketed briefly in <span class="inline text-[1em] leading-7">France</span> but was <span class="inline text-[1em] leading-7">withdrawn from the market</span> due to <span class="inline text-[1em] leading-7">liver toxicity</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_vgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<h4 id="etifoxine" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Etifoxine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Etifoxine</span> has similar anxiolytic effects as benzodiazepine drugs, but does not produce the same levels of sedation and <span class="inline text-[1em] leading-7">ataxia</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Further, etifoxine does not affect memory and vigilance, and does not induce rebound anxiety, <span class="inline text-[1em] leading-7">drug dependence</span>, or withdrawal symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup></span>
<h4 id="alcohol" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Alcohol<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Alcohol</span> is sometimes used as an anxiolytic by <span class="inline text-[1em] leading-7">self-medication</span>. <span class="inline text-[1em] leading-7">fMRI</span> can measure the anxiolytic effects of alcohol in the human brain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<h2 id="alternatives-to-medication" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Alternatives to medication<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Cognitive behavioral therapy</span> (CBT) is an effective treatment for <span class="inline text-[1em] leading-7">panic disorder</span>, <span class="inline text-[1em] leading-7">social anxiety disorder</span>, <span class="inline text-[1em] leading-7">generalized anxiety disorder</span>, and <span class="inline text-[1em] leading-7">obsessive–compulsive disorder</span>, while <span class="inline text-[1em] leading-7">exposure therapy</span> is the recommended treatment for anxiety related phobias. Healthcare providers can guide those with anxiety disorder by referring them to self-help resources.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_rjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> Other non-medication options include mindfulness-based therapies and lifestyle interventions such as exercise and improved sleep hygiene.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_vjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Combined medication and psychotherapy can be more effective than either alone in some cases, particularly for severe anxiety, though evidence varies by disorder and treatment type.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">If CBT is found ineffective or inaccessible, major guidelines from organizations like the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the American Psychiatric Association (APA) recommend considering medication.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20090628224336/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/100020674.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Antianxiety agent&quot;</a> at <em><span class="inline text-[1em] leading-7">Dorland&#x27;s Medical Dictionary</span></em></span></div></li><li id="https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK470361/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK470361/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK470361/</a></span></div></li><li id="https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961</a></span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Whittlesea, Cate; Hodson, Karen, eds. (7 August 2018). <em>Clinical pharmacy and therapeutics</em>. Elsevier. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-7020-7012-9. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/1084882482" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1084882482</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/health/treatments/24776-anxiolytics" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Anxiolytics and you: How anxiety medications can help&quot;</a>. <em>Cleveland Clinic</em>. Retrieved 15 January 2024.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.camh.ca/en/professionals/treating-conditions-and-disorders/anxiety-disorders/anxiety---treatment/anxiety---pharmacotherapy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Anxiety: Pharmacotherapy&quot;</a>. <em>CAMH</em>. Retrieved 15 January 2024.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Garakani, Amir; Murrough, James W.; Freire, Rafael C.; Thom, Robyn P.; Larkin, Kaitlyn; Buono, Frank D.; Iosifescu, Dan V. (2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options&quot;</a>. <em>Frontiers in Psychiatry</em>. <strong>11</strong>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3389%2Ffpsyt.2020.595584" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3389/fpsyt.2020.595584</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1664-0640" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1664-0640</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7786299</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33424664" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33424664</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Psychopharmacology of anxiety disorders&quot;</a>. <em>Dialogues in Clinical Neuroscience</em>. <strong>4</strong> (3): 271–285. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.31887/DCNS.2002.4.3/gcassano</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1294-8322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1294-8322</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3181684</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22033867" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22033867</a>.</span></div></li><li id="https://journals.sagepub.com/doi/pdf/10.1177/070674370505000702" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/pdf/10.1177/070674370505000702" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/pdf/10.1177/070674370505000702</a></span></div></li><li id="https://www.benzoinfo.com/a-brief-history-of-benzodiazepines/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.benzoinfo.com/a-brief-history-of-benzodiazepines/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.benzoinfo.com/a-brief-history-of-benzodiazepines/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S104366182400255X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S104366182400255X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S104366182400255X</a></span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Van Der Walt, Martie; Keddy, Karen H. (1 June 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The Tuberculosis-Depression Syndemic and Evolution of Pharmaceutical Therapeutics: From Ancient Times to the Future&quot;</a>. <em>Frontiers in Psychiatry</em>. <strong>12</strong> : 617751. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3389%2Ffpsyt.2021.617751" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3389/fpsyt.2021.617751</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1664-0640" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1664-0640</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8203803</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34140898" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34140898</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hillhouse, Todd M.; Porter, Joseph H. (2015). <a href="https://dx.doi.org/10.1037/a0038550" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A brief history of the development of antidepressant drugs: From monoamines to glutamate&quot;</a>. <em>Experimental and Clinical Psychopharmacology</em>. <strong>23</strong> (1): 1–21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1037%2Fa0038550" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1037/a0038550</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1936-2293" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1936-2293</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428540" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4428540</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25643025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25643025</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Moraczewski, Jordan; Awosika, Ayoola O.; Aedma, Kapil K. (2023), <a href="https://www.ncbi.nlm.nih.gov/books/NBK557791/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tricyclic Antidepressants&quot;</a>, <em>StatPearls</em> , Treasure Island (FL): StatPearls Publishing, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32491723" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32491723</a>, retrieved 15 January 2024</span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/19810918/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/19810918/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/19810918/</a></span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dx.doi.org/10.1016/b978-0-7020-3471-8.00064-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Rang and Dale&#x27;s Pharmacology 7th Edition Preface&quot;</a>, <em>Rang &amp;amp Dale&#x27;s Pharmacology</em>, Elsevier, pp. xv, 2012, <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fb978-0-7020-3471-8.00064-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/b978-0-7020-3471-8.00064-0</a>, <span class="inline text-[1em] leading-7">ISBN</span> 9780702034718, retrieved 16 March 2022</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/health/treatments/24570-benzodiazepines-benzos" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Benzodiazepines: What They Are, Uses, Side Effects &amp; Risks&quot;</a>. <em>Cleveland Clinic</em>. Retrieved 15 January 2024.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.klarityadhd.com/post/buspar-for-anxiety-is-it-right-for-me/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;BuSpar For Anxiety: Is It Right For Me? | Klarity&quot;</a>. <em><a href="http://www.klarityadhd.com" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.klarityadhd.com</a></em>. 23 November 2022. Retrieved 19 October 2023.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychcentral.com/anxiety/antipsychotics-anticonvulsants-for-anxiety-disorders" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;What is the Best Anticonvulsant for Anxiety?&quot;</a>. <em>Psych Central</em>. 28 October 2014. Retrieved 19 October 2023.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kanba, S. (2004). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs?&quot;</a>. <em>Journal of Psychiatry &amp; Neuroscience</em>. <strong>29</strong> (6): 485. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">524966</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15644990" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15644990</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Barlow, David H.; Durand, Mark V (2009). &quot;Chapter 7: Mood Disorders and Suicide&quot;. <em>Abnormal Psychology: An Integrative Approach</em> (Fifth ed.). Belmont, CA: Wadsworth Cengage Learning. p. 239. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-495-09556-9. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/192055408" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">192055408</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lochmann, Dee; Richardson, Tara (2018), Macaluso, Matthew; Preskorn, Sheldon H. (eds.), <a href="http://link.springer.com/10.1007/164_2018_172" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Selective Serotonin Reuptake Inhibitors&quot;</a>, <em>Antidepressants</em> , vol. 250, Cham: Springer International Publishing, pp. 135–144, <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2F164_2018_172" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/164_2018_172</a>, <span class="inline text-[1em] leading-7">ISBN</span> 978-3-030-10948-6, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30838457" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30838457</a>, retrieved 16 March 2022</span></div></li><li id="https://www.apa.org/ptsd-guideline/treatments/medications" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.apa.org/ptsd-guideline/treatments/medications" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.apa.org/ptsd-guideline/treatments/medications</a></span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/health/articles/22572-serotonin" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Serotonin: What Is It, Function &amp; Levels&quot;</a>. <em>Cleveland Clinic</em>. Retrieved 15 January 2024.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Dunlop, Boadie W.; Davis, Paula G. (2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review&quot;</a>. <em>Primary Care Companion to the Journal of Clinical Psychiatry</em>. <strong>10</strong> (3): 222–228. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4088%2Fpcc.v10n0307" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4088/pcc.v10n0307</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1523-5998" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1523-5998</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2446479</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18615162" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18615162</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Formulary., Committee, Joint (2014). <em>British National Formulary</em>. Pharmaceutical Press. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-85711-152-4. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/874322467" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">874322467</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: multiple names: authors list (link)</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Stahl, Stephen M. (2011). <em>Stahl&#x27;s essential psychopharmacology  : the prescriber&#x27;s guide</em>. Meghan M. Grady (4th ed.). Cambridge, UK: Cambridge University Press. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-521-17364-3. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/701672553" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">701672553</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/side-effects/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Side effects - Selective serotonin reuptake inhibitors (SSRIs)&quot;</a>. <em>nhs.uk</em>. 15 February 2021. Retrieved 15 January 2024.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bandelow, Borwin; Michaelis, Sophie; Wedekind, Dirk (June 2017). <a href="https://dx.doi.org/10.31887/dcns.2017.19.2/bbandelow" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Treatment of anxiety disorders&quot;</a>. <em>Generalized Anxiety Disorders</em>. <strong>19</strong> (2): 93–107. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.31887%2Fdcns.2017.19.2%2Fbbandelow" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.31887/dcns.2017.19.2/bbandelow</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2608-3477" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2608-3477</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573566" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5573566</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28867934" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28867934</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">John Vanin; James Helsley (19 June 2008). <em>Anxiety Disorders: A Pocket Guide For Primary Care</em>. Springer Science &amp; Business Media. p. 189.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Post, Jason W.; Migne, Louis J. (2012). <em>Antidepressants  : Pharmacology, Health Effects and Controversy</em>. New York: Nova Science Publishers. p. 58. <span class="inline text-[1em] leading-7">ISBN</span> 9781620815557.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tricyclic antidepressants (TCAs)&quot;</a>. <em><span class="inline text-[1em] leading-7">Mayo Clinic</span></em>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Thanacoody, H. K. Ruben; Thomas, Simon H. L. (2005). &quot;Tricyclic antidepressant poisoning : cardiovascular toxicity&quot;. <em>Toxicological Reviews</em>. <strong>24</strong> (3): 205–214. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2165%2F00139709-200524030-00013" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2165/00139709-200524030-00013</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1176-2551" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1176-2551</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16390222" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16390222</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:44532041" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">44532041</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Montano, C. Brendan; Jackson, W. Clay; Vanacore, Denise; Weisler, Richard (4 July 2023). <a href="https://doi.org/10.1080%2F00325481.2023.2189868" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression&quot;</a>. <em>Postgraduate Medicine</em>. <strong>135</strong> (5): 449–465. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F00325481.2023.2189868" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/00325481.2023.2189868</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0032-5481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0032-5481</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/36912037" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36912037</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tanghe, A.; Geerts, S.; Van Dorpe, J.; Brichard, B.; Bruhwyler, J.; Géczy, J. (August 1997). &quot;Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression&quot;. <em>Acta Psychiatrica Scandinavica</em>. <strong>96</strong> (2): 134–141. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1600-0447.1997.tb09918.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1600-0447.1997.tb09918.x</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0001-690X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0001-690X</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9272198" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9272198</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:23485112" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23485112</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Burchum, Jacqueline Rosenjack; Rosenthal, Laura D. (29 January 2015). <em>Lehne&#x27;s pharmacology for nursing care</em> (9th ed.). St. Louis, Missouri. <span class="inline text-[1em] leading-7">ISBN</span> 9780323321907. <span class="inline text-[1em] leading-7">OCLC</span> <a href="https://search.worldcat.org/oclc/890310283" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">890310283</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: CS1 maint: location missing publisher (link)</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Psychopharmacology of anxiety disorders&quot;</a>. <em>Dialogues in Clinical Neuroscience</em>. <strong>4</strong> (3): 271–285. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.31887/DCNS.2002.4.3/gcassano</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1294-8322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1294-8322</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3181684</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22033867" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22033867</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp236.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lader M, Tylee A, Donoghue J (2009). &quot;Withdrawing benzodiazepines in primary care&quot;. <em>CNS Drugs</em>. <strong>23</strong> (1): 19–34. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2165%2F0023210-200923010-00002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2165/0023210-200923010-00002</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19062773" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19062773</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:113206" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">113206</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">George, Tobin T.; Tripp, Jayson (2025), <a href="https://www.ncbi.nlm.nih.gov/books/NBK538165/#" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Alprazolam&quot;</a>, <em>StatPearls</em> , Treasure Island (FL): StatPearls Publishing, <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30844192" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30844192</a>, retrieved 22 April 2025</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hayes, Peggy E.; Schulz, S. Charles (1987). <a href="https://zenodo.org/record/1258347" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Beta-blockers in anxiety disorders&quot;</a>. <em>Journal of Affective Disorders</em>. <strong>13</strong> (2): 119–30. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0165-0327%2887%2990017-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0165-0327(87)90017-6</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2890677" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2890677</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Jefferson, James W. (1974). &quot;Beta-Adrenergic Receptor Blocking Drugs in Psychiatry&quot;. <em>Archives of General Psychiatry</em>. <strong>31</strong> (5): 681–91. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1001%2Farchpsyc.1974.01760170071012" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1001/archpsyc.1974.01760170071012</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/4155284" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4155284</a>.</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Koola, M. M.; Varghese, S. P.; Fawcett, J. A. (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;High-dose prazosin for the treatment of post-traumatic stress disorder&quot;</a>. <em>Therapeutic Advances in Psychopharmacology</em>. <strong>4</strong> (1): 43–7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1177%2F2045125313500982" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1177/2045125313500982</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3896131</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24490030" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24490030</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hoehn-Saric, Rudolf; Merchant, A. F.; Keyser, M. L.; Smith, V. K. (1981). &quot;Effects of Clonidine on Anxiety Disorders&quot;. <em>Archives of General Psychiatry</em>. <strong>38</strong> (11): 1278–82. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1001%2Farchpsyc.1981.01780360094011" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1001/archpsyc.1981.01780360094011</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7305609" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7305609</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://books.google.com/books?id=oJY8LrP_JysC&amp;q=%22Azapirone%22+%225-HT1A%22+%22receptor%22+%22Sediel%22&amp;pg=PA319" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Annual Reports in Medicinal Chemistry, Volume 32 p. 319</em></a></span></div></li><li id="40" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">DeMartinis, N.; Rynn, M.; Rickels, K.; Mandos, L. (February 2000). &quot;Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder&quot;. <em>The Journal of Clinical Psychiatry</em>. <strong>61</strong> (2): 91–94. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4088%2Fjcp.v61n0203" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4088/jcp.v61n0203</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0160-6689" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0160-6689</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/10732655" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10732655</a>.</span></div></li><li id="41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bandelow, Borwin; Wedekind, Dirk; Leon, Teresa (2014). &quot;Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention&quot;. <em>Expert Review of Neurotherapeutics</em>. <strong>7</strong> (7): 769–81. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1586%2F14737175.7.7.769" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1586/14737175.7.7.769</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17610384" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17610384</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6229344" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6229344</a>.</span></div></li><li id="42" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Owen, R.T. (2007). &quot;Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety&quot;. <em>Drugs of Today</em>. <strong>43</strong> (9): 601–10. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1358%2Fdot.2007.43.9.1133188" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1358/dot.2007.43.9.1133188</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17940637" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17940637</a>.</span></div></li><li id="43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Llorca, Pierre-Michel; Spadone, Christian; Sol, Olivier; Danniau, Anne; Bougerol, Thierry; Corruble, Emmanuelle; Faruch, Michel; Macher, Jean-Paul; Sermet, Eric; Servant, Dominique (2002). &quot;Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder&quot;. <em>The Journal of Clinical Psychiatry</em>. <strong>63</strong> (11): 1020–7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4088%2FJCP.v63n1112" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4088/JCP.v63n1112</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12444816" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12444816</a>.</span></div></li><li id="44" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lapin, Izyaslav (2001). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phenibut (β-Phenyl-GABA): A Tranquilizer and Nootropic Drug&quot;</a>. <em>CNS Drug Reviews</em>. <strong>7</strong> (4): 471–481. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1527-3458.2001.tb00211.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1527-3458.2001.tb00211.x</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1527-3458" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1527-3458</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6494145</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11830761" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11830761</a>.</span></div></li><li id="45" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">журнал», Издание для практикующих врачей «Русский медицинский. <a href="http://www.rmj.ru/articles/nevrologiya/Fenomen_aminofenilmaslyanoy_kisloty/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Феномен аминофенилмасляной кислоты&quot;</a>. <em><a href="http://www.rmj.ru" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.rmj.ru</a></em>. Retrieved 19 December 2018.</span></div></li><li id="46" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zvejniece, Liga; Vavers, Edijs; Svalbe, Baiba; Veinberg, Grigory; Rizhanova, Kristina; Liepins, Vilnis; Kalvinsh, Ivars; Dambrova, Maija (1 October 2015). &quot;R-phenibut binds to the α2–δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects&quot;. <em>Pharmacology Biochemistry and Behavior</em>. <strong>137</strong> : 23–29. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.pbb.2015.07.014" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.pbb.2015.07.014</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0091-3057" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0091-3057</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26234470" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26234470</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:42606053" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">42606053</a>.</span></div></li><li id="47" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Owen, David R.; Wood, David M.; Archer, John R. H.; Dargan, Paul I. (2016). &quot;Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity&quot;. <em>Drug and Alcohol Review</em>. <strong>35</strong> (5): 591–596. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fdar.12356" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/dar.12356</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10044%2F1%2F30073" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10044/1/30073</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1465-3362" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1465-3362</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26693960" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26693960</a>.</span></div></li><li id="48" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cohen, Pieter A.; Ellison, Ross R.; Travis, John C.; Gaufberg, Slava V.; Gerona, Roy (22 September 2021). &quot;Quantity of phenibut in dietary supplements before and after FDA warnings&quot;. <em>Clinical Toxicology</em>. <strong>60</strong> (4): 486–488. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F15563650.2021.1973020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/15563650.2021.1973020</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34550038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34550038</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:237594860" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">237594860</a>.</span></div></li><li id="49" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20151203130342/http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Adaptol. Summary of Product Characteristics&quot;</a> (PDF). Archived from <a href="http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 3 December 2015. Retrieved 24 July 2015.</span></div></li><li id="50" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Val&#x27;dman AV, Zaikonnikova IV, Kozlovskaia MM, Zimakova IE (1980). &quot;[Characteristics of the psychotropic spectrum of action of mebicar]&quot;. <em>Biulleten&#x27; Eksperimental&#x27;noĭ Biologii I Meditsiny</em> (in Russian). <strong>89</strong> (5): 568–70. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/6104993" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6104993</a>.</span></div></li><li id="51" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). &quot;Clinical study of the selective anxiolytic agent afobazol&quot;. <em>Eksperimental&#x27;naia i Klinicheskaia Farmakologiia</em>. <strong>64</strong> (2): 15–9. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11548440" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11548440</a>.</span></div></li><li id="52" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Silkina, IV; Gan&#x27;shina, TC; Seredin, SB; Mirzoian, RS (2005). &quot;Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon&quot;. <em>Eksperimental&#x27;naia i Klinicheskaia Farmakologiia</em>. <strong>68</strong> (1): 20–4. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15786959" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15786959</a>.</span></div></li><li id="53" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vakhitova IuV, Iamidanov RS, Seredinin SB (2004). &quot;[Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]&quot;. <em>Eksp Klin Farmakol</em> (in Russian). <strong>67</strong> (4): 7–11. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15500036" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15500036</a>.</span></div></li><li id="54" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vakhitova, Yu. V.; Yamidanov, R. S.; Vakhitov, V. A.; Seredenin, S. B. (2005). &quot;The effect of ladasten on gene expression in the rat brain&quot;. <em>Doklady Biochemistry and Biophysics</em>. <strong>401</strong> (1–6): 150–153. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs10628-005-0057-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s10628-005-0057-z</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1607-6729" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1607-6729</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15999825" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15999825</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:28048257" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28048257</a>.</span></div></li><li id="55" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Volchegorskii, I. A.; Miroshnichenko, I. Yu.; Rassokhina, L. M.; Faizullin, R. M.; Malkin, M. P.; Pryakhina, K. E.; Kalugina, A. V. (2015). &quot;Comparative Analysis of the Anxiolytic Effects of 3-Hydroxypyridine and Succinic Acid Derivatives&quot;. <em>Bulletin of Experimental Biology and Medicine</em>. <strong>158</strong> (6): 756–61. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs10517-015-2855-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s10517-015-2855-3</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25894772" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25894772</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6052275" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6052275</a>.</span></div></li><li id="56" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rumyantseva, S. A.; Fedin, A. I.; Sokhova, O. N. (2012). &quot;Antioxidant Treatment of Ischemic Brain Lesions&quot;. <em>Neuroscience and Behavioral Physiology</em>. <strong>42</strong> (8): 842–5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs11055-012-9646-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s11055-012-9646-3</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:39971165" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">39971165</a>. <span class="inline text-[1em] leading-7">INIST</span> <a href="https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26388033" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26388033</a>.</span></div></li><li id="57" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://encyclopedia2.thefreedictionary.com/Validol" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Validol&quot;</a>. <em>The Great Soviet Encyclopedia</em>.</span></div></li><li id="58" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20131219200018/http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Farmak Product Information - Validol&quot;</a> (PDF). Archived from <a href="http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 19 December 2013. Retrieved 9 April 2013.</span></div></li><li id="59" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Malykh, Andrei G.; Sadaie, M. Reza (2010). &quot;Piracetam and Piracetam-Like Drugs&quot;. <em>Drugs</em>. <strong>70</strong> (3): 287–312. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2165%2F11319230-000000000-00000" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2165/11319230-000000000-00000</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20166767" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20166767</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:12176745" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12176745</a>.</span></div></li><li id="60" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Skolnick P (November 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Anxioselective anxiolytics: on a quest for the Holy Grail&quot;</a>. <em>Trends Pharmacol Sci</em>. <strong>33</strong> (11): 611–20. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.tips.2012.08.003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.tips.2012.08.003</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3482271</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22981367" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22981367</a>.</span></div></li><li id="61" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nuss, Philippe; Ferreri, Florian; Bourin, Michel (2019). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action (Review)&quot;</a>. <em>Neuropsychiatric Disease and Treatment</em>. <strong>15</strong> : 1781–1795. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.2147%2Fndt.s200568" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.2147/ndt.s200568</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1178-2021" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1178-2021</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6615018</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31308671" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31308671</a>.</span></div></li><li id="62" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gilman, J. M.; Ramchandani, V. A.; Davis, M. B.; Bjork, J. M.; Hommer, D. W. (2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol&quot;</a>. <em>Journal of Neuroscience</em>. <strong>28</strong> (18): 4583–91. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1523%2FJNEUROSCI.0086-08.2008" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1523/JNEUROSCI.0086-08.2008</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2730732</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18448634" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18448634</a>.</span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/17868756/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/17868756/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/17868756/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7001348/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7001348/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7001348/</a></span></div></li><li id="https://psychiatryonline.org/doi/full/10.1176/appi.focus.20200045" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/full/10.1176/appi.focus.20200045" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/full/10.1176/appi.focus.20200045</a></span></div></li><li id="https://www.canmat.org/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.canmat.org/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.canmat.org/</a></span></div></li><li id="https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Anxiolytic" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0" id="_R_" async=""></script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Anxiolytic\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Anxiolytic\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Anxiolytic\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T77a6,"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"# Anxiolytic\n\nAn **anxiolytic** (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also **anti-anxiety agent**)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.\n# Nature of Anxiety\n\nAnxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, [anxiety disorders](Anxiety_disorder \"Anxiety disorder\") may occur. People with anxiety disorders can exhibit fear responses, such as defensive behaviors, high levels of alertness, and [negative emotions](Negative_emotion \"Negative emotion\"). Those with anxiety disorders may have concurrent psychological disorders, such as [depression](Depression_\\(mood\\) \"Depression \\(mood\\)\"). Anxiety disorders are classified according to criteria in the DSM-5.[](https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders) Common types include:\n\n| Type | Description |\n|------|-------------|\n| [Generalized anxiety disorder (GAD)](Generalized_Anxiety_Disorder \"Generalized Anxiety Disorder\") | The anxiety symptoms are usually persistent and constant. Patients of this disorder could experience excessive anxiety for a long duration, commonly over six months and the symptoms could occur without any specific triggers. |\n| [Panic disorder](Panic_disorder \"Panic disorder\") | This disorder specifically refers to the suffering from panic attacks and also the fear of repetitive attacks. It is often associated with agoraphobia (the fear of situations where escape might be difficult). Panic attacks are sudden upsurges in anxiety level usually with unexplained reasons. |\n| [Social anxiety disorder](Social_anxiety_disorder \"Social anxiety disorder\") | This refers to the fear of engaging in social situations where one experiences public observation among people or performs in front of the public. The fears are often unexplained and persistent. The fear could also be attributed to the possible humiliation in front of others due to poor performance or awkward social interactions. |\n| [Specific phobias](Specific_phobia \"Specific phobia\") | Persistent fear towards a specific object, either tangible or intangible. This leads to undeniable avoidance or thought of escape from the object or endurance of the object in immense levels of anxiety. |\n| [Agoraphobia](Agoraphobia \"Agoraphobia\") | Intense fear or anxiety triggered by exposure to situations where escape might be difficult or help unavailable, such as open spaces, crowds, or public transportation. Often leads to avoidance behaviors. |\n| [Separation anxiety disorder](Separation_anxiety_disorder \"Separation anxiety disorder\") | Excessive fear or anxiety concerning separation from home or attachment figures, inappropriate for the individual's developmental level. Symptoms include distress when anticipating or experiencing separation. |\n\nDifferent types of anxiety disorders will share some general symptoms while having their own distinctive symptoms. This explains why people with different types of anxiety disorders will respond differently to different classes of anti-anxiety medications.\n# Etiology\n\nThe etiology of anxiety disorders is multifactorial and involves an interaction of genetic vulnerability with environmental and psychological factors.[](https://www.ncbi.nlm.nih.gov/books/NBK470361/)\n\nRisk factors include a family history of anxiety disorders, traumatic or stressful life events, adverse childhood experiences, certain medical conditions such as metabolic or endocrine disorders (e.g., hyperthyroidism, diabetes), substance use or withdrawal including central nervous system stimulants, and comorbid psychiatric conditions like depression.[](https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961) [2]\n## Medications\n\nAnti-anxiety medication is any drug that can be taken or prescribed for the treatment of anxiety disorders, which may be mediated by neurotransmitters like norepinephrine, serotonin, dopamine, and gamma-aminobutyric acid (GABA) in the central nervous system.[3] Anti-anxiety medication can be classified into six types according to their different mechanisms: antidepressants, benzodiazepines, azapirones, antiepileptics, antipsychotics, and beta blockers.[3][4]\n\nAntidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs and SNRIs are both used as first-line treatments across various anxiety disorders, including generalized anxiety disorder (GAD).[14] TCAs are second-line treatment as they cause more significant adverse effects when compared to the first-line treatment. Benzodiazepines are effective in emergent and short-term treatment of anxiety disorders due to their fast onset but carry the risk of dependence.[4] Buspirone is indicated for GAD, which has much slower onset but with the advantage of less sedating and withdrawal effects.[5]\n## History\n\nThe use of anxiolytics dates back to the 19th century with sedatives like bromides and chloral hydrate. Barbiturates, introduced in 1903 with barbital, became the first widely used class for treating anxiety and insomnia, though they carried high risks of dependence and overdose.[](https://journals.sagepub.com/doi/pdf/10.1177/070674370505000702)\n\nIn the 1950s, non-barbiturate sedatives emerged, including meprobamate (approved 1955), which was marketed as a safer alternative for anxiety. The benzodiazepine class revolutionized anxiolytic treatment when chlordiazepoxide (Librium) was synthesized in 1955 and approved in 1960, followed by diazepam (Valium) in 1963. These agents targeted the GABA_A receptor, providing effective anxiety relief with lower toxicity than barbiturates.[](https://www.benzoinfo.com/a-brief-history-of-benzodiazepines/); [](https://www.sciencedirect.com/science/article/pii/S104366182400255X)\n\nThe first monoamine oxidase inhibitor (MAOI), iproniazid, was discovered accidentally in 1951 while developing the antitubercular drug isoniazid. It was found to induce euphoria and improve patients' appetite and sleep quality.[6]\n\nThe first tricyclic antidepressant (TCA), imipramine, was originally developed and studied as an antihistamine alongside other first-generation antihistamines of the time, such as promethazine.[7] TCAs increase the levels of norepinephrine and serotonin by inhibiting their reuptake transport proteins.[8] Many TCAs also have significant anticholinergic and antihistaminergic properties, leading to side effects like drowsiness and memory loss.\n\nTo achieve greater selectivity for serotonin reuptake inhibition and avoid anticholinergic and antihistaminergic side effects, selective serotonin reuptake inhibitors (SSRIs) were developed. The first SSRI, fluoxetine (Prozac), was synthesized in 1972, patented in 1974, and approved by the FDA in 1987 for depression; it was later used for anxiety disorders. Subsequently, other SSRIs such as sertraline (Zoloft, approved 1991), paroxetine (Paxil, approved 1992), and escitalopram (Lexapro, approved 2002) entered the market.[7]; [](https://en.wikipedia.org/wiki/Fluoxetine)\n\nThe first serotonin-norepinephrine reuptake inhibitor (SNRI), venlafaxine (Effexor), was approved for depression in 1993 and later for anxiety.[7] SNRIs target serotonin and norepinephrine transporters while having minimal effects on other adrenergic (α1, α2, and β), histamine (H1), muscarinic, dopamine, or postsynaptic serotonin receptors.[](https://pubmed.ncbi.nlm.nih.gov/19810918/)\n# Classifications\n\nThere are six groups of anti-anxiety medications available that have been proven to be clinically significant in treatment of anxiety disorders.[10] The groups of medications are as follows. \n\n| Drug Class | Examples |\n|------------|----------|\n| [Antidepressants](Antidepressant \"Antidepressant\") (e.g., SSRIs, SNRIs) | SSRIs e.g., fluoxetine, sertraline; SNRIs e.g., venlafaxine; MAOIs; TCAs |\n| [Benzodiazepines](Benzodiazepine \"Benzodiazepine\") | Lorazepam, diazepam, alprazolam |\n| [Azapirones](Azapirone \"Azapirone\") | Buspirone, gepirone, tandospirone |\n| [Antiepileptics](Anticonvulsant \"Anticonvulsant\") | Gabapentin, pregabalin, tiagabine and valproate |\n| [Antipsychotics](Antipsychotic \"Antipsychotic\") | Olanzapine, risperidone |\n| [Beta-adrenoceptor antagonists](Beta_blocker \"Beta blocker\") | Propranolol, atenolol |\n\n### Antidepressants\n\nMedications that are indicated for both anxiety disorders and depression. [Selective serotonin reuptake inhibitors](Selective_serotonin_reuptake_inhibitor \"Selective serotonin reuptake inhibitor\") (SSRIs) and [serotonin–norepinephrine reuptake inhibitors](Serotonin%E2%80%93norepinephrine_reuptake_inhibitor \"Serotonin–norepinephrine reuptake inhibitor\") (SNRIs) are new generations of antidepressants. They have a much lower adverse effect profile than older antidepressants like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Therefore, SSRIs and SNRIs are now the first-line agent in treating long term anxiety disorders, given their applications and significance in all six types of disorders.[10]\n\n### Benzodiazepines\n\n[Benzodiazepines](Benzodiazepine \"Benzodiazepine\") are used for acute anxiety and could be added along with current use of SSRIs to stabilize a treatment. Long-term use in treatment plans is not recommended. Different kinds of benzodiazepine will vary in its pharmacological profile, including its strength of effect and time taken for metabolism. The choice of the benzodiazepine will depend on the corresponding profiles.[10]\n\nBenzodiazepines are used for emergent or short-term management. They are not recommended as the first-line anti-anxiety drugs, but they can be used in combination with SSRIs/SNRIs during the initial treatment stage.[4] Indications include panic disorder, sleep disorders, seizures, acute behavioral disturbance, muscle spasm and premedication and sedation for procedures.[11]\n\n### Azapirones\n\n[Buspirone](Buspirone \"Buspirone\") can be useful in GAD but not particularly effective in treating phobias, panic disorder or social anxiety disorders.[2] It is a safer option for long-term use as it does not cause dependence like benzodiazepines.[12]\n\n### Antiepileptics\n\nAntiepileptics are rarely prescribed as an off-label treatment for anxiety disorders and post-traumatic stress disorders.[13] There have been some suggestions that they may help with anxiety symptoms but there is generally a lack of research on its use.[14]\n\nOne antiepileptic, [pregabalin](Pregabalin \"Pregabalin\"), has been found to be better at treating GAD than a placebo, and comparable effects to benzodiazepines. It has also been shown be potentially efficient in treating social anxiety disorder. [Gabapentin](Gabapentin \"Gabapentin\") has been prescribed off-label for anxiety despite a lack of research evidence supporting such use, although some studies have indicated that it may relieve anxiety symptoms. The potential anxiolytic effect of [tiagabine](Tiagabine \"Tiagabine\") has been observed in some pre-clinical trials, but its effectiveness has not yet been proved. Similarly, there is a lack of research on [valproate](Valproate \"Valproate\") for the treatment of anxiety disorders.[14]\n\n### Antipsychotics\n\n[Olanzapine](Olanzapine \"Olanzapine\") and [risperidone](Risperidone \"Risperidone\") are atypical antipsychotics which are also effective in GAD and PTSD treatment. However, there is a higher chance of experiencing adverse effects than the other anti-anxiety medications.[10]\n\n### Beta-adrenoceptor antagonists\n\n[Propranolol](Propranolol \"Propranolol\") is originally used for high blood pressure and heart diseases. It can also be used to treat anxiety with symptoms like tremor or increased heart rate. They work on the nervous system and alleviate the symptoms as a relief.[10] Propranolol is also commonly used for public speaking when one is nervous.[14]\n## Mechanism of action\n\n### SSRIs and SNRIs\n\nSelective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) inhibit the reuptake of serotonin (and norepinephrine for SNRIs) by blocking their respective transporters on presynaptic neurons, thereby increasing the concentration of these neurotransmitters in the synaptic cleft and enhancing postsynaptic signaling.[10] While the precise mechanisms underlying their anxiolytic effects are not fully understood, they are thought to involve adaptive changes in serotonergic (and noradrenergic) systems, such as desensitization of presynaptic 5-HT1A autoreceptors, which initially limit serotonin release but, over time (typically 4–6 weeks), allow for sustained enhancement of transmission.[2][10]\n\n### Benzodiazepine\n\nBenzodiazepines bind selectively to the [GABA receptor](GABA_receptor \"GABA receptor\"), which is the receptor protein found in the nervous system and is in control of the nervous response. Benzodiazepine will increase the entry of chloride ions into the cells by improving the binding between [GABA](Gamma-Aminobutyric_acid \"Gamma-Aminobutyric acid\") and GABA receptors and then the better opening of the channel for chloride ion passage. The high level of chloride ion inside the nerve cells makes the nerve more difficult to [depolarize](Depolarization \"Depolarization\") and inhibit further nerve signal transduction. The excitability of the nerves then reduces and the nervous system slows down. Therefore, the drug can alleviate symptoms of anxiety disorder and make the person less nervous.[10]\n## Clinical use\n\n### Selective serotonin reuptake inhibitors\n\n[Selective serotonin reuptake inhibitors](Selective_serotonin_reuptake_inhibitors \"Selective serotonin reuptake inhibitors\") (SSRIs) are a class of medications used in the treatment of [depression](Major_depressive_disorder \"Major depressive disorder\"), [anxiety disorders](Anxiety_disorder \"Anxiety disorder\"), [OCD](Obsessive%E2%80%93compulsive_disorder \"Obsessive–compulsive disorder\") and some [personality disorders](Personality_disorder \"Personality disorder\").[15][16] SSRIs are the first-line anti-anxiety medications.[17] As of 2025, SSRIs remain first-line per major guidelines (e.g., APA, NICE).[](https://www.apa.org/ptsd-guideline/treatments/medications) Serotonin is one of the crucial neurotransmitters in mood enhancement, and increasing serotonin level produces an anti-anxiety effect.[18] SSRIs increase the serotonin level in the brain by inhibiting serotonin uptake pumps on serotonergic systems, without interactions with other receptors and ion channels. SSRIs are beneficial in both acute response and long-term maintenance treatment for both depression and anxiety disorder.[17]\n\nSSRIs can increase anxiety initially due to negative feedback through the serotonergic [autoreceptors](Autoreceptors \"Autoreceptors\"); for this reason a concurrent benzodiazepine can be used until the anxiolytic effect of the SSRI occurs.[19]\n\nThe SSRIs [paroxetine](Paroxetine \"Paroxetine\") and [escitalopram](Escitalopram \"Escitalopram\") are [USFDA](Food_and_Drug_Administration \"Food and Drug Administration\") approved to treat generalized anxiety disorder.[14]\n\n#### Therapeutic use\n\n| Drug | Indication | Common side effect |\n|------|------------|--------------------|\n| [Citalopram](Citalopram \"Citalopram\") | Depressive illness[20]\u003cbr\u003ePanic disorder[17] | Apathy (caused by decrease in dopamine release)\u003cbr\u003eFlatulence\u003cbr\u003eDrowsiness[21]\u003cbr\u003e[Migraine](Migraine \"Migraine\")\u003cbr\u003e[Rhinitis](Rhinitis \"Rhinitis\") |\n| [Escitalopram](Escitalopram \"Escitalopram\")[20] (active enantiomer of citalopram) | Depressive illness\u003cbr\u003eGeneralized anxiety disorder\u003cbr\u003eObsessive-compulsive disorder\u003cbr\u003ePanic disorder\u003cbr\u003eSocial anxiety disorder | [Sinusitis](Sinusitis \"Sinusitis\") |\n| [Fluoxetine](Fluoxetine \"Fluoxetine\")[20] | [Major depression](Major_depressive_disorder \"Major depressive disorder\")\u003cbr\u003e[Bulimia nervosa](Bulimia_nervosa \"Bulimia nervosa\")\u003cbr\u003eObsessive-compulsive disorder\u003cbr\u003eMenopausal symptoms | Chills\u003cbr\u003eFeeling abnormal\u003cbr\u003ePostmenopausal [hemorrhage](Hemorrhage \"Hemorrhage\")\u003cbr\u003eUterine disorder\u003cbr\u003eVasodilation\u003cbr\u003eBlurred vision |\n\n#### Adverse effect\n\nThe common early side effects of SSRIs include nausea and loose stool, which can be solved by discontinuing the treatment. Headache, dizziness, insomnia are the common early side effects as well.[22]\n\n[Sexual dysfunction](Sexual_dysfunction \"Sexual dysfunction\"), [anorgasmia](Anorgasmia \"Anorgasmia\"), [erectile dysfunction](Erectile_dysfunction \"Erectile dysfunction\"), and [reduced libido](Reduced_libido \"Reduced libido\") are common adverse side effects of SSRIs. Sometimes they [may persist after the cessation of treatment](Post-SSRI_Sexual_Dysfunction \"Post-SSRI Sexual Dysfunction\").[22]\n\n[Withdrawal symptoms](Drug_withdrawal \"Drug withdrawal\") like dizziness, headache and flu-like symptoms (fatigue/myalgia/loose stool) may occur if SSRI is stopped suddenly. The brain is incapable of upregulating the receptors to sufficient levels especially after discontinuation of the drugs with short half-life like paroxetine. Both fluoxetine and its active metabolite have a long half-life therefore it causes the least withdrawal symptoms.[17][23]\n\n### Serotonin–norepinephrine reuptake inhibitors\n\n[Serotonin–norepinephrine reuptake inhibitor](Serotonin%E2%80%93norepinephrine_reuptake_inhibitor \"Serotonin–norepinephrine reuptake inhibitor\") (SNRIs) include [venlafaxine](Venlafaxine \"Venlafaxine\") and [duloxetine](Duloxetine \"Duloxetine\") drugs. Venlafaxine, in [extended release](Extended_release \"Extended release\") form, and duloxetine, are indicated for the treatment of [GAD](Generalized_anxiety_disorder \"Generalized anxiety disorder\"). SNRIs are as effective as SSRIs in the treatment of anxiety disorders.[24]\n\n### Tricyclic antidepressants\n\n[Tricyclic antidepressants](Tricyclic_antidepressants \"Tricyclic antidepressants\") (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. They are considered effective, but have generally been replaced by antidepressants that cause different adverse effects. Examples include [imipramine](Imipramine \"Imipramine\"), [doxepin](Doxepin \"Doxepin\"), [amitriptyline](Amitriptyline \"Amitriptyline\"), [nortriptyline](Nortriptyline \"Nortriptyline\") and [desipramine](Desipramine \"Desipramine\").[25][26]\n\n#### Therapeutic use\n\n| Drugs | Indication | Common side effect |\n|-------|------------|--------------------|\n| [Imipramine](Imipramine \"Imipramine\") | Nocturnal [enuresis](Enuresis \"Enuresis\") for children above six years old\u003cbr\u003eSevere depression | Antihistamine side effects like sedation, weight gain\u003cbr\u003eAnticholinergic side effects like blurred vision, dry mouth, constipation |\n| [Clomipramine](Clomipramine \"Clomipramine\")[20] | Depressive illness\u003cbr\u003ePhobic and obsessional states\u003cbr\u003eAdjunctive treatment of [cataplexy](Cataplexy \"Cataplexy\") associated with [narcolepsy](Narcolepsy \"Narcolepsy\") | [Arrhythmias](Arrhythmia \"Arrhythmia\")\u003cbr\u003eBreast enlargement\u003cbr\u003eDry mouth\u003cbr\u003eConstipation\u003cbr\u003eDrowsiness\u003cbr\u003eDizziness |\n\n#### Contraindication\n\nTCAs are contraindicated in patients with [hypotension](Hypotension \"Hypotension\"), cardiovascular diseases and arrhythmias due to risk of toxicity and exacerbation.[27]\n\n### Tetracyclic antidepressants\n\n[Mirtazapine](Mirtazapine \"Mirtazapine\") has demonstrated anxiolytic effect comparable to SSRIs while rarely causing or exacerbating anxiety. Mirtazapine's anxiety reduction tends to occur significantly faster than SSRIs.[28]\n\n### Monoamine oxidase inhibitors\n\n[Monoamine oxidase inhibitors](Monoamine_oxidase_inhibitors \"Monoamine oxidase inhibitors\") (MAOIs) are first-generation antidepressants effective for anxiety treatment but their dietary restrictions, adverse effect profile and availability of newer medications have limited their use. MAOIs include [phenelzine](Phenelzine \"Phenelzine\"), [isocarboxazid](Isocarboxazid \"Isocarboxazid\") and [tranylcypromine](Tranylcypromine \"Tranylcypromine\"). [Pirlindole](Pirlindole \"Pirlindole\") is a reversible MAOI that lacks dietary restriction.[29]\n\n### Barbiturates\n\n[Barbiturates](Barbiturate \"Barbiturate\") are powerful anxiolytics but the risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.[30]\n\n### Benzodiazepines\n\n[Benzodiazepines](Benzodiazepine \"Benzodiazepine\") are prescribed to quell [panic attacks](Panic_attacks \"Panic attacks\"). Benzodiazepines are also prescribed in tandem with an antidepressant for the latent period of efficacy associated with many ADs for anxiety disorder. There is risk of [benzodiazepine withdrawal](Benzodiazepine_withdrawal \"Benzodiazepine withdrawal\") and [rebound syndrome](Rebound_syndrome \"Rebound syndrome\") if BZDs are rapidly discontinued.[31] Tolerance and dependence may occur.[32] The risk of abuse in this class of medication is smaller than in that of barbiturates. Cognitive and behavioral adverse effects are possible.[33]\n\nBenzodiazepines include: [alprazolam](Alprazolam \"Alprazolam\") (Xanax), [bromazepam](Bromazepam \"Bromazepam\"), [chlordiazepoxide](Chlordiazepoxide \"Chlordiazepoxide\") (Librium), [clonazepam](Clonazepam \"Clonazepam\") (Klonopin), [diazepam](Diazepam \"Diazepam\") (Valium), [lorazepam](Lorazepam \"Lorazepam\") (Ativan), [oxazepam](Oxazepam \"Oxazepam\"), [temazepam](Temazepam \"Temazepam\"), and [Triazolam](Triazolam \"Triazolam\"). \n\n#### Therapeutic use\n\n| Drug | Indication | Common side effect |\n|------|------------|--------------------|\n| Lorazepam | Short term use in anxiety\u003cbr\u003eShort term use in insomnia associated anxiety\u003cbr\u003e[Conscious sedation](Procedural_sedation_and_analgesia \"Procedural sedation and analgesia\") for procedures\u003cbr\u003ePremedication\u003cbr\u003e[Status epilepticus/febrile convulsions/convulsions](Epilepsy \"Epilepsy\") caused by poisoning | Decreased alertness\u003cbr\u003e[Ataxia](Ataxia \"Ataxia\"), confusion (more in elderly) |\n| Diazepam | Muscle spasm of varied aetiology\u003cbr\u003eAnxiety\u003cbr\u003eAcute drug-induced dystonic reactions\u003cbr\u003eSedation for minor surgical and medical procedures | Abnormal appetite\u003cbr\u003eConcentration impairment\u003cbr\u003eGastrointestinal disorder\u003cbr\u003eMovement disorder\u003cbr\u003eMuscle spasm\u003cbr\u003eVomiting |\n| Alprazolam | Short term use in anxiety | Poor balance or coordination\u003cbr\u003eChanges in speech patterns\u003cbr\u003eDecreased alertness\u003cbr\u003eIrritability[34] |\n\n#### Adverse effect\n\nBenzodiazepines lead to [central nervous system depression](Central_nervous_system_depression \"Central nervous system depression\"), resulting in common adverse effects like drowsiness, oversedation, light-headedness. Memory impairment can be a common adverse effect especially in elderly, hypersalivation, ataxia, slurred speech, psychomotor effects.[2]\n\n### Sympatholytics\n\n[Sympatholytics](Sympatholytic \"Sympatholytic\") are a group of anti-hypertensives which inhibit activity of the [sympathetic nervous system](Sympathetic_nervous_system \"Sympathetic nervous system\"). [Beta blockers](Beta_blockers \"Beta blockers\") reduce anxiety by decreasing heart rate and preventing shaking. Beta blockers include [propranolol](Propranolol \"Propranolol\"), [oxprenolol](Oxprenolol \"Oxprenolol\"), and [metoprolol](Metoprolol \"Metoprolol\").[35][36] The alpha-1 antagonist [prazosin](Prazosin \"Prazosin\") could be effective for PTSD.[37] The alpha-2 agonists [clonidine](Clonidine \"Clonidine\") and [guanfacine](Guanfacine \"Guanfacine\") have demonstrated both anxiolytic and anxiogenic effects.[38]\n\n### Miscellaneous\n\n#### Buspirone\n\n[Buspirone](Buspirone \"Buspirone\") (Buspar) is a [5-HT1A receptor](5-HT1A_receptor \"5-HT1A receptor\") [agonist](Agonist \"Agonist\") used to treated generalized anxiety disorder.[39] If an individual has only recently stopped taking benzodiazepines, buspirone will be less effective.[40]\n\n#### Pregabalin\n\n[Pregabalin](Pregabalin \"Pregabalin\") (Lyrica) produces anxiolytic effect after one week of use comparable to [lorazepam](Lorazepam \"Lorazepam\"), [alprazolam](Alprazolam \"Alprazolam\"), and [venlafaxine](Venlafaxine \"Venlafaxine\") with more consistent psychic and somatic anxiety reduction. Unlike BZDs, it does not disrupt [sleep architecture](Sleep_architecture \"Sleep architecture\") nor does it cause cognitive or psychomotor impairment.[41][42]\n\n#### Hydroxyzine\n\n[Hydroxyzine](Hydroxyzine \"Hydroxyzine\") (Atarax) is an [antihistamine](Antihistamine \"Antihistamine\") originally approved for clinical use by the FDA in 1956. Hydroxyzine has a calming effect which helps ameliorate anxiety. Hydroxyzine efficacy is comparable to benzodiazepines in the treatment of [generalized anxiety disorder](Generalized_anxiety_disorder \"Generalized anxiety disorder\").[43]\n\n#### Phenibut\n\n[Phenibut](Phenibut \"Phenibut\") (Anvifen, Fenibut, Noofen) is an anxiolytic[44] used in Russia.[45] Phenibut is a [GABAB receptor](GABAB_receptor \"GABAB receptor\") [agonist](Agonist \"Agonist\"),[44] as well as an antagonist at [α2δ subunit](Voltage-dependent_calcium_channel \"Voltage-dependent calcium channel\")-containing [voltage-dependent calcium channels](Voltage-dependent_calcium_channel \"Voltage-dependent calcium channel\") (VDCCs), similarly to [gabapentinoids](Gabapentinoid \"Gabapentinoid\") like [gabapentin](Gabapentin \"Gabapentin\") and [pregabalin](Pregabalin \"Pregabalin\").[46] The medication is not approved by the FDA for use in the United States, but is sold online as a supplement.[47][48]\n\n#### Temgicoluril\n\n[Temgicoluril](Temgicoluril \"Temgicoluril\") (Mebicar) is an anxiolytic produced in [Latvia](Latvia \"Latvia\") and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the [hypothalamus](Hypothalamus \"Hypothalamus\"), as well as on all four basic neuromediator systems – [γ aminobutyric acid](Gamma-aminobutyric_acid \"Gamma-aminobutyric acid\") (GABA), [choline](Choline \"Choline\"), [serotonin](Serotonin \"Serotonin\") and adrenergic activity.[49] Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.[50]\n\n#### Fabomotizole\n\n[Fabomotizole](Fabomotizole \"Fabomotizole\") (Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. Its mechanism of action is poorly defined, with GABAergic, [NGF](Nerve_growth_factor \"Nerve growth factor\") and [BDNF](Brain-derived_neurotrophic_factor \"Brain-derived neurotrophic factor\") release promoting, [MT1 receptor](Melatonin_receptor \"Melatonin receptor\") agonism, MT3 receptor antagonism, and [sigma receptor](Sigma_receptor \"Sigma receptor\") agonism thought to have some involvement.[51][52]\n\n#### Bromantane\n\n[Bromantane](Bromantane \"Bromantane\") is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s. Bromantane acts mainly by facilitating the biosynthesis of dopamine, through indirect genomic upregulation of relevant enzymes ([tyrosine hydroxylase](Tyrosine_hydroxylase \"Tyrosine hydroxylase\") (TH) and [aromatic L-amino acid decarboxylase](Aromatic_L-amino_acid_decarboxylase \"Aromatic L-amino acid decarboxylase\") (AAAD)).[53][54]\n\n#### Emoxypine\n\n[Emoxypine](Emoxypine \"Emoxypine\") is an [antioxidant](Antioxidant \"Antioxidant\") that is also a purported anxiolytic.[55][56] Its chemical structure resembles that of [pyridoxine](Pyridoxine \"Pyridoxine\"), a form of vitamin B6. \n\n#### Menthyl isovalerate\n\n[Menthyl isovalerate](Menthyl_isovalerate \"Menthyl isovalerate\") is a flavoring food additive marketed as a [sedative](Sedative \"Sedative\") and anxiolytic drug in Russia under the name _Validol_.[57][58]\n\n#### Racetams\n\nSome [racetam](Racetam \"Racetam\") based drugs such as [aniracetam](Aniracetam \"Aniracetam\") can have an antianxiety effect.[59]\n\n#### Alpidem\n\n[Alpidem](Alpidem \"Alpidem\") is a [nonbenzodiazepine](Nonbenzodiazepine \"Nonbenzodiazepine\") anxiolytic with similar anxiolytic effectiveness as benzodiazepines but reduced [sedation](Sedation \"Sedation\") and cognitive, memory, and motor impairment.[60] It was marketed briefly in [France](France \"France\") but was [withdrawn from the market](List_of_withdrawn_drugs \"List of withdrawn drugs\") due to [liver toxicity](Liver_toxicity \"Liver toxicity\").[60]\n\n#### Etifoxine\n\n[Etifoxine](Etifoxine \"Etifoxine\") has similar anxiolytic effects as benzodiazepine drugs, but does not produce the same levels of sedation and [ataxia](Ataxia \"Ataxia\").[61] Further, etifoxine does not affect memory and vigilance, and does not induce rebound anxiety, [drug dependence](Drug_dependence \"Drug dependence\"), or withdrawal symptoms.[61]\n\n#### Alcohol\n\n[Alcohol](Alcohol_\\(drug\\) \"Alcohol \\(drug\\)\") is sometimes used as an anxiolytic by [self-medication](Self-medication \"Self-medication\"). [fMRI](FMRI \"FMRI\") can measure the anxiolytic effects of alcohol in the human brain.[62]\n## Alternatives to medication\n\n[Cognitive behavioral therapy](Cognitive_behavioral_therapy \"Cognitive behavioral therapy\") (CBT) is an effective treatment for [panic disorder](Panic_disorder \"Panic disorder\"), [social anxiety disorder](Social_anxiety_disorder \"Social anxiety disorder\"), [generalized anxiety disorder](Generalized_anxiety_disorder \"Generalized anxiety disorder\"), and [obsessive–compulsive disorder](Obsessive%E2%80%93compulsive_disorder \"Obsessive–compulsive disorder\"), while [exposure therapy](Exposure_therapy \"Exposure therapy\") is the recommended treatment for anxiety related phobias. Healthcare providers can guide those with anxiety disorder by referring them to self-help resources.[](https://pubmed.ncbi.nlm.nih.gov/17868756/) Other non-medication options include mindfulness-based therapies and lifestyle interventions such as exercise and improved sleep hygiene.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001348/)\n\nCombined medication and psychotherapy can be more effective than either alone in some cases, particularly for severe anxiety, though evidence varies by disorder and treatment type.[](https://psychiatryonline.org/doi/full/10.1176/appi.focus.20200045)\n\nIf CBT is found ineffective or inaccessible, major guidelines from organizations like the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the American Psychiatric Association (APA) recommend considering medication.[](https://www.canmat.org/)[](https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines)"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886654152,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [\\\"Antianxiety agent\\\"](https://web.archive.org/web/20090628224336/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/100020674.htm) at _[Dorland's Medical Dictionary](Dorland's_medical_reference_works \\\"Dorland's medical reference works\\\")_\",\"description\":\"1. **^** [\\\"Antianxiety agent\\\"](https://web.archive.org/web/20090628224336/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/100020674.htm) at _[Dorland's Medical Dictionary](Dorland's_medical_reference_works \\\"Dorland's medical reference works\\\")_\",\"url\":\"https://web.archive.org/web/20090628224336/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/100020674.htm\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Whittlesea, Cate; Hodson, Karen, eds. (7 August 2018). _Clinical pharmacy and therapeutics_. Elsevier. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7020-7012-9. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [1084882482](https://search.worldcat.org/oclc/1084882482).\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Whittlesea, Cate; Hodson, Karen, eds. (7 August 2018). _Clinical pharmacy and therapeutics_. Elsevier. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7020-7012-9. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [1084882482](https://search.worldcat.org/oclc/1084882482).\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ [\\\"Anxiolytics and you: How anxiety medications can help\\\"](https://my.clevelandclinic.org/health/treatments/24776-anxiolytics). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"description\":\"3. ^ _**a**_ _**b**_ [\\\"Anxiolytics and you: How anxiety medications can help\\\"](https://my.clevelandclinic.org/health/treatments/24776-anxiolytics). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"url\":\"https://my.clevelandclinic.org/health/treatments/24776-anxiolytics\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ [\\\"Anxiety: Pharmacotherapy\\\"](https://www.camh.ca/en/professionals/treating-conditions-and-disorders/anxiety-disorders/anxiety---treatment/anxiety---pharmacotherapy). _CAMH_. Retrieved 15 January 2024.\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ [\\\"Anxiety: Pharmacotherapy\\\"](https://www.camh.ca/en/professionals/treating-conditions-and-disorders/anxiety-disorders/anxiety---treatment/anxiety---pharmacotherapy). _CAMH_. Retrieved 15 January 2024.\",\"url\":\"https://www.camh.ca/en/professionals/treating-conditions-and-disorders/anxiety-disorders/anxiety---treatment/anxiety---pharmacotherapy\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). [\\\"Psychopharmacology of anxiety disorders\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). _Dialogues in Clinical Neuroscience_. **4** (3): 271–285\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/DCNS.2002.4.3/gcassano](https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1294-8322](https://search.worldcat.org/issn/1294-8322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3181684](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22033867](https://pubmed.ncbi.nlm.nih.gov/22033867).\",\"description\":\"5. **^** Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). [\\\"Psychopharmacology of anxiety disorders\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). _Dialogues in Clinical Neuroscience_. **4** (3): 271–285\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/DCNS.2002.4.3/gcassano](https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1294-8322](https://search.worldcat.org/issn/1294-8322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3181684](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22033867](https://pubmed.ncbi.nlm.nih.gov/22033867).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Van Der Walt, Martie; Keddy, Karen H. (1 June 2021). [\\\"The Tuberculosis-Depression Syndemic and Evolution of Pharmaceutical Therapeutics: From Ancient Times to the Future\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803). _Frontiers in Psychiatry_. **12** : 617751. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fpsyt.2021.617751](https://doi.org/10.3389%2Ffpsyt.2021.617751). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1664-0640](https://search.worldcat.org/issn/1664-0640). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8203803](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34140898](https://pubmed.ncbi.nlm.nih.gov/34140898).\",\"description\":\"6. **^** Van Der Walt, Martie; Keddy, Karen H. (1 June 2021). [\\\"The Tuberculosis-Depression Syndemic and Evolution of Pharmaceutical Therapeutics: From Ancient Times to the Future\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803). _Frontiers in Psychiatry_. **12** : 617751. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fpsyt.2021.617751](https://doi.org/10.3389%2Ffpsyt.2021.617751). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1664-0640](https://search.worldcat.org/issn/1664-0640). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8203803](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34140898](https://pubmed.ncbi.nlm.nih.gov/34140898).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203803\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ _**c**_ Hillhouse, Todd M.; Porter, Joseph H. (2015). [\\\"A brief history of the development of antidepressant drugs: From monoamines to glutamate\\\"](https://dx.doi.org/10.1037/a0038550). _Experimental and Clinical Psychopharmacology_. **23** (1): 1–21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1037/a0038550](https://doi.org/10.1037%2Fa0038550). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1936-2293](https://search.worldcat.org/issn/1936-2293). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4428540](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428540). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25643025](https://pubmed.ncbi.nlm.nih.gov/25643025).\",\"description\":\"7. ^ _**a**_ _**b**_ _**c**_ Hillhouse, Todd M.; Porter, Joseph H. (2015). [\\\"A brief history of the development of antidepressant drugs: From monoamines to glutamate\\\"](https://dx.doi.org/10.1037/a0038550). _Experimental and Clinical Psychopharmacology_. **23** (1): 1–21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1037/a0038550](https://doi.org/10.1037%2Fa0038550). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1936-2293](https://search.worldcat.org/issn/1936-2293). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4428540](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428540). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25643025](https://pubmed.ncbi.nlm.nih.gov/25643025).\",\"url\":\"https://dx.doi.org/10.1037/a0038550\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Moraczewski, Jordan; Awosika, Ayoola O.; Aedma, Kapil K. (2023), [\\\"Tricyclic Antidepressants\\\"](https://www.ncbi.nlm.nih.gov/books/NBK557791/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32491723](https://pubmed.ncbi.nlm.nih.gov/32491723), retrieved 15 January 2024\",\"description\":\"8. **^** Moraczewski, Jordan; Awosika, Ayoola O.; Aedma, Kapil K. (2023), [\\\"Tricyclic Antidepressants\\\"](https://www.ncbi.nlm.nih.gov/books/NBK557791/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32491723](https://pubmed.ncbi.nlm.nih.gov/32491723), retrieved 15 January 2024\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK557791/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Chu, Andrew; Wadhwa, Roopma (2025), [\\\"Selective Serotonin Reuptake Inhibitors\\\"](https://www.ncbi.nlm.nih.gov/books/NBK554406/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32119293](https://pubmed.ncbi.nlm.nih.gov/32119293), retrieved 22 April 2025\",\"description\":\"9. **^** Chu, Andrew; Wadhwa, Roopma (2025), [\\\"Selective Serotonin Reuptake Inhibitors\\\"](https://www.ncbi.nlm.nih.gov/books/NBK554406/), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32119293](https://pubmed.ncbi.nlm.nih.gov/32119293), retrieved 22 April 2025\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK554406/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ [\\\"Rang and Dale's Pharmacology 7th Edition Preface\\\"](https://dx.doi.org/10.1016/b978-0-7020-3471-8.00064-0), _Rang \u0026amp Dale's Pharmacology_, Elsevier, pp. xv, 2012, [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/b978-0-7020-3471-8.00064-0](https://doi.org/10.1016%2Fb978-0-7020-3471-8.00064-0), [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780702034718, retrieved 16 March 2022\",\"description\":\"10. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ [\\\"Rang and Dale's Pharmacology 7th Edition Preface\\\"](https://dx.doi.org/10.1016/b978-0-7020-3471-8.00064-0), _Rang \u0026amp Dale's Pharmacology_, Elsevier, pp. xv, 2012, [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/b978-0-7020-3471-8.00064-0](https://doi.org/10.1016%2Fb978-0-7020-3471-8.00064-0), [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780702034718, retrieved 16 March 2022\",\"url\":\"https://dx.doi.org/10.1016/b978-0-7020-3471-8.00064-0\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** [\\\"Benzodiazepines: What They Are, Uses, Side Effects \u0026 Risks\\\"](https://my.clevelandclinic.org/health/treatments/24570-benzodiazepines-benzos). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"description\":\"11. **^** [\\\"Benzodiazepines: What They Are, Uses, Side Effects \u0026 Risks\\\"](https://my.clevelandclinic.org/health/treatments/24570-benzodiazepines-benzos). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"url\":\"https://my.clevelandclinic.org/health/treatments/24570-benzodiazepines-benzos\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** [\\\"BuSpar For Anxiety: Is It Right For Me? | Klarity\\\"](https://www.klarityadhd.com/post/buspar-for-anxiety-is-it-right-for-me/). _www.klarityadhd.com_. 23 November 2022. Retrieved 19 October 2023.\",\"description\":\"12. **^** [\\\"BuSpar For Anxiety: Is It Right For Me? | Klarity\\\"](https://www.klarityadhd.com/post/buspar-for-anxiety-is-it-right-for-me/). _www.klarityadhd.com_. 23 November 2022. Retrieved 19 October 2023.\",\"url\":\"https://www.klarityadhd.com/post/buspar-for-anxiety-is-it-right-for-me/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** [\\\"What is the Best Anticonvulsant for Anxiety?\\\"](https://psychcentral.com/anxiety/antipsychotics-anticonvulsants-for-anxiety-disorders). _Psych Central_. 28 October 2014. Retrieved 19 October 2023.\",\"description\":\"13. **^** [\\\"What is the Best Anticonvulsant for Anxiety?\\\"](https://psychcentral.com/anxiety/antipsychotics-anticonvulsants-for-anxiety-disorders). _Psych Central_. 28 October 2014. Retrieved 19 October 2023.\",\"url\":\"https://psychcentral.com/anxiety/antipsychotics-anticonvulsants-for-anxiety-disorders\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Garakani, Amir; Murrough, James W.; Freire, Rafael C.; Thom, Robyn P.; Larkin, Kaitlyn; Buono, Frank D.; Iosifescu, Dan V. (2020). [\\\"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299). _Frontiers in Psychiatry_. **11**. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fpsyt.2020.595584](https://doi.org/10.3389%2Ffpsyt.2020.595584). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1664-0640](https://search.worldcat.org/issn/1664-0640). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7786299](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33424664](https://pubmed.ncbi.nlm.nih.gov/33424664).\",\"description\":\"14. ^ _**a**_ _**b**_ _**c**_ _**d**_ Garakani, Amir; Murrough, James W.; Freire, Rafael C.; Thom, Robyn P.; Larkin, Kaitlyn; Buono, Frank D.; Iosifescu, Dan V. (2020). [\\\"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299). _Frontiers in Psychiatry_. **11**. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fpsyt.2020.595584](https://doi.org/10.3389%2Ffpsyt.2020.595584). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1664-0640](https://search.worldcat.org/issn/1664-0640). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7786299](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33424664](https://pubmed.ncbi.nlm.nih.gov/33424664).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Kanba, S. (2004). [\\\"Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs?\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966). _Journal of Psychiatry \u0026 Neuroscience_. **29** (6): 485. [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [524966](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15644990](https://pubmed.ncbi.nlm.nih.gov/15644990).\",\"description\":\"15. **^** Kanba, S. (2004). [\\\"Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs?\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966). _Journal of Psychiatry \u0026 Neuroscience_. **29** (6): 485. [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [524966](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15644990](https://pubmed.ncbi.nlm.nih.gov/15644990).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524966\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Barlow, David H.; Durand, Mark V (2009). \\\"Chapter 7: Mood Disorders and Suicide\\\". _Abnormal Psychology: An Integrative Approach_ (Fifth ed.). Belmont, CA: Wadsworth Cengage Learning. p. 239\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-495-09556-9. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [192055408](https://search.worldcat.org/oclc/192055408).\",\"description\":\"16. **^** Barlow, David H.; Durand, Mark V (2009). \\\"Chapter 7: Mood Disorders and Suicide\\\". _Abnormal Psychology: An Integrative Approach_ (Fifth ed.). Belmont, CA: Wadsworth Cengage Learning. p. 239\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-495-09556-9. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [192055408](https://search.worldcat.org/oclc/192055408).\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Lochmann, Dee; Richardson, Tara (2018), Macaluso, Matthew; Preskorn, Sheldon H. (eds.), [\\\"Selective Serotonin Reuptake Inhibitors\\\"](http://link.springer.com/10.1007/164_2018_172), _Antidepressants_ , vol. 250, Cham: Springer International Publishing, pp. 135–144, [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/164_2018_172](https://doi.org/10.1007%2F164_2018_172), [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-3-030-10948-6, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30838457](https://pubmed.ncbi.nlm.nih.gov/30838457), retrieved 16 March 2022\",\"description\":\"17. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Lochmann, Dee; Richardson, Tara (2018), Macaluso, Matthew; Preskorn, Sheldon H. (eds.), [\\\"Selective Serotonin Reuptake Inhibitors\\\"](http://link.springer.com/10.1007/164_2018_172), _Antidepressants_ , vol. 250, Cham: Springer International Publishing, pp. 135–144, [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/164_2018_172](https://doi.org/10.1007%2F164_2018_172), [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-3-030-10948-6, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30838457](https://pubmed.ncbi.nlm.nih.gov/30838457), retrieved 16 March 2022\",\"url\":\"http://link.springer.com/10.1007/164_2018_172\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** [\\\"Serotonin: What Is It, Function \u0026 Levels\\\"](https://my.clevelandclinic.org/health/articles/22572-serotonin). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"description\":\"18. **^** [\\\"Serotonin: What Is It, Function \u0026 Levels\\\"](https://my.clevelandclinic.org/health/articles/22572-serotonin). _Cleveland Clinic_. Retrieved 15 January 2024.\",\"url\":\"https://my.clevelandclinic.org/health/articles/22572-serotonin\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Dunlop, Boadie W.; Davis, Paula G. (2008). [\\\"Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479). _Primary Care Companion to the Journal of Clinical Psychiatry_. **10** (3): 222–228\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/pcc.v10n0307](https://doi.org/10.4088%2Fpcc.v10n0307). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1523-5998](https://search.worldcat.org/issn/1523-5998). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2446479](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18615162](https://pubmed.ncbi.nlm.nih.gov/18615162).\",\"description\":\"19. **^** Dunlop, Boadie W.; Davis, Paula G. (2008). [\\\"Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479). _Primary Care Companion to the Journal of Clinical Psychiatry_. **10** (3): 222–228\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/pcc.v10n0307](https://doi.org/10.4088%2Fpcc.v10n0307). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1523-5998](https://search.worldcat.org/issn/1523-5998). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2446479](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18615162](https://pubmed.ncbi.nlm.nih.gov/18615162).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446479\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Formulary., Committee, Joint (2014). _British National Formulary_. Pharmaceutical Press. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-85711-152-4. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [874322467](https://search.worldcat.org/oclc/874322467).`{{cite book}}`: CS1 maint: multiple names: authors list (link)\",\"description\":\"20. ^ _**a**_ _**b**_ _**c**_ _**d**_ Formulary., Committee, Joint (2014). _British National Formulary_. Pharmaceutical Press. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-85711-152-4. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [874322467](https://search.worldcat.org/oclc/874322467).`{{cite book}}`: CS1 maint: multiple names: authors list (link)\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Stahl, Stephen M. (2011). _Stahl's essential psychopharmacology  : the prescriber's guide_. Meghan M. Grady (4th ed.). Cambridge, UK: Cambridge University Press. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-521-17364-3. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [701672553](https://search.worldcat.org/oclc/701672553).\",\"description\":\"21. **^** Stahl, Stephen M. (2011). _Stahl's essential psychopharmacology  : the prescriber's guide_. Meghan M. Grady (4th ed.). Cambridge, UK: Cambridge University Press. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-521-17364-3. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [701672553](https://search.worldcat.org/oclc/701672553).\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"_**a**_ _**b**_ [\\\"Side effects - Selective serotonin reuptake inhibitors (SSRIs)\\\"](https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/side-effects/). _nhs.uk_. 15 February 2021. Retrieved 15 January 2024.\",\"description\":\"22. ^ _**a**_ _**b**_ [\\\"Side effects - Selective serotonin reuptake inhibitors (SSRIs)\\\"](https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/side-effects/). _nhs.uk_. 15 February 2021. Retrieved 15 January 2024.\",\"url\":\"https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/side-effects/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Bandelow, Borwin; Michaelis, Sophie; Wedekind, Dirk (June 2017). [\\\"Treatment of anxiety disorders\\\"](https://dx.doi.org/10.31887/dcns.2017.19.2/bbandelow). _Generalized Anxiety Disorders_. **19** (2): 93–107\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/dcns.2017.19.2/bbandelow](https://doi.org/10.31887%2Fdcns.2017.19.2%2Fbbandelow). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2608-3477](https://search.worldcat.org/issn/2608-3477). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5573566](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573566). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28867934](https://pubmed.ncbi.nlm.nih.gov/28867934).\",\"description\":\"23. **^** Bandelow, Borwin; Michaelis, Sophie; Wedekind, Dirk (June 2017). [\\\"Treatment of anxiety disorders\\\"](https://dx.doi.org/10.31887/dcns.2017.19.2/bbandelow). _Generalized Anxiety Disorders_. **19** (2): 93–107\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/dcns.2017.19.2/bbandelow](https://doi.org/10.31887%2Fdcns.2017.19.2%2Fbbandelow). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2608-3477](https://search.worldcat.org/issn/2608-3477). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5573566](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573566). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28867934](https://pubmed.ncbi.nlm.nih.gov/28867934).\",\"url\":\"https://dx.doi.org/10.31887/dcns.2017.19.2/bbandelow\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** John Vanin; James Helsley (19 June 2008). _Anxiety Disorders: A Pocket Guide For Primary Care_. Springer Science \u0026 Business Media. p. 189.\",\"description\":\"24. **^** John Vanin; James Helsley (19 June 2008). _Anxiety Disorders: A Pocket Guide For Primary Care_. Springer Science \u0026 Business Media. p. 189.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Post, Jason W.; Migne, Louis J. (2012). _Antidepressants  : Pharmacology, Health Effects and Controversy_. New York: Nova Science Publishers. p. 58\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781620815557.\",\"description\":\"25. **^** Post, Jason W.; Migne, Louis J. (2012). _Antidepressants  : Pharmacology, Health Effects and Controversy_. New York: Nova Science Publishers. p. 58\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9781620815557.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** [\\\"Tricyclic antidepressants (TCAs)\\\"](https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983). _[Mayo Clinic](Mayo_Clinic \\\"Mayo Clinic\\\")_.\",\"description\":\"26. **^** [\\\"Tricyclic antidepressants (TCAs)\\\"](https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983). _[Mayo Clinic](Mayo_Clinic \\\"Mayo Clinic\\\")_.\",\"url\":\"https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Thanacoody, H. K. Ruben; Thomas, Simon H. L. (2005). \\\"Tricyclic antidepressant poisoning : cardiovascular toxicity\\\". _Toxicological Reviews_. **24** (3): 205–214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/00139709-200524030-00013](https://doi.org/10.2165%2F00139709-200524030-00013). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1176-2551](https://search.worldcat.org/issn/1176-2551). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16390222](https://pubmed.ncbi.nlm.nih.gov/16390222). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [44532041](https://api.semanticscholar.org/CorpusID:44532041).\",\"description\":\"27. **^** Thanacoody, H. K. Ruben; Thomas, Simon H. L. (2005). \\\"Tricyclic antidepressant poisoning : cardiovascular toxicity\\\". _Toxicological Reviews_. **24** (3): 205–214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/00139709-200524030-00013](https://doi.org/10.2165%2F00139709-200524030-00013). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1176-2551](https://search.worldcat.org/issn/1176-2551). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16390222](https://pubmed.ncbi.nlm.nih.gov/16390222). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [44532041](https://api.semanticscholar.org/CorpusID:44532041).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Montano, C. Brendan; Jackson, W. Clay; Vanacore, Denise; Weisler, Richard (4 July 2023). [\\\"Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression\\\"](https://doi.org/10.1080%2F00325481.2023.2189868). _Postgraduate Medicine_. **135** (5): 449–465\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/00325481.2023.2189868](https://doi.org/10.1080%2F00325481.2023.2189868). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0032-5481](https://search.worldcat.org/issn/0032-5481). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36912037](https://pubmed.ncbi.nlm.nih.gov/36912037).\",\"description\":\"28. **^** Montano, C. Brendan; Jackson, W. Clay; Vanacore, Denise; Weisler, Richard (4 July 2023). [\\\"Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression\\\"](https://doi.org/10.1080%2F00325481.2023.2189868). _Postgraduate Medicine_. **135** (5): 449–465\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/00325481.2023.2189868](https://doi.org/10.1080%2F00325481.2023.2189868). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0032-5481](https://search.worldcat.org/issn/0032-5481). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36912037](https://pubmed.ncbi.nlm.nih.gov/36912037).\",\"url\":\"https://doi.org/10.1080%2F00325481.2023.2189868\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Tanghe, A.; Geerts, S.; Van Dorpe, J.; Brichard, B.; Bruhwyler, J.; Géczy, J. (August 1997). \\\"Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression\\\". _Acta Psychiatrica Scandinavica_. **96** (2): 134–141\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1600-0447.1997.tb09918.x](https://doi.org/10.1111%2Fj.1600-0447.1997.tb09918.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0001-690X](https://search.worldcat.org/issn/0001-690X). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9272198](https://pubmed.ncbi.nlm.nih.gov/9272198). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23485112](https://api.semanticscholar.org/CorpusID:23485112).\",\"description\":\"29. **^** Tanghe, A.; Geerts, S.; Van Dorpe, J.; Brichard, B.; Bruhwyler, J.; Géczy, J. (August 1997). \\\"Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression\\\". _Acta Psychiatrica Scandinavica_. **96** (2): 134–141\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1600-0447.1997.tb09918.x](https://doi.org/10.1111%2Fj.1600-0447.1997.tb09918.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0001-690X](https://search.worldcat.org/issn/0001-690X). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9272198](https://pubmed.ncbi.nlm.nih.gov/9272198). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23485112](https://api.semanticscholar.org/CorpusID:23485112).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Burchum, Jacqueline Rosenjack; Rosenthal, Laura D. (29 January 2015). _Lehne's pharmacology for nursing care_ (9th ed.). St. Louis, Missouri. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780323321907. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [890310283](https://search.worldcat.org/oclc/890310283).`{{cite book}}`: CS1 maint: location missing publisher (link)\",\"description\":\"30. **^** Burchum, Jacqueline Rosenjack; Rosenthal, Laura D. (29 January 2015). _Lehne's pharmacology for nursing care_ (9th ed.). St. Louis, Missouri. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780323321907. [OCLC](OCLC_\\\\(identifier\\\\) \\\"OCLC \\\\(identifier\\\\)\\\") [890310283](https://search.worldcat.org/oclc/890310283).`{{cite book}}`: CS1 maint: location missing publisher (link)\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). [\\\"Psychopharmacology of anxiety disorders\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). _Dialogues in Clinical Neuroscience_. **4** (3): 271–285\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/DCNS.2002.4.3/gcassano](https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1294-8322](https://search.worldcat.org/issn/1294-8322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3181684](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22033867](https://pubmed.ncbi.nlm.nih.gov/22033867).\",\"description\":\"31. **^** Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). [\\\"Psychopharmacology of anxiety disorders\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). _Dialogues in Clinical Neuroscience_. **4** (3): 271–285\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.31887/DCNS.2002.4.3/gcassano](https://doi.org/10.31887%2FDCNS.2002.4.3%2Fgcassano). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1294-8322](https://search.worldcat.org/issn/1294-8322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3181684](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22033867](https://pubmed.ncbi.nlm.nih.gov/22033867).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181684\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp236.\",\"description\":\"32. **^** Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp236.\",\"url\":\"\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Lader M, Tylee A, Donoghue J (2009). \\\"Withdrawing benzodiazepines in primary care\\\". _CNS Drugs_. **23** (1): 19–34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/0023210-200923010-00002](https://doi.org/10.2165%2F0023210-200923010-00002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19062773](https://pubmed.ncbi.nlm.nih.gov/19062773). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [113206](https://api.semanticscholar.org/CorpusID:113206).\",\"description\":\"33. **^** Lader M, Tylee A, Donoghue J (2009). \\\"Withdrawing benzodiazepines in primary care\\\". _CNS Drugs_. **23** (1): 19–34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/0023210-200923010-00002](https://doi.org/10.2165%2F0023210-200923010-00002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19062773](https://pubmed.ncbi.nlm.nih.gov/19062773). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [113206](https://api.semanticscholar.org/CorpusID:113206).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** George, Tobin T.; Tripp, Jayson (2025), [\\\"Alprazolam\\\"](https://www.ncbi.nlm.nih.gov/books/NBK538165/#), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30844192](https://pubmed.ncbi.nlm.nih.gov/30844192), retrieved 22 April 2025\",\"description\":\"34. **^** George, Tobin T.; Tripp, Jayson (2025), [\\\"Alprazolam\\\"](https://www.ncbi.nlm.nih.gov/books/NBK538165/#), _StatPearls_ , Treasure Island (FL): StatPearls Publishing, [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30844192](https://pubmed.ncbi.nlm.nih.gov/30844192), retrieved 22 April 2025\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK538165/#\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** Hayes, Peggy E.; Schulz, S. Charles (1987). [\\\"Beta-blockers in anxiety disorders\\\"](https://zenodo.org/record/1258347). _Journal of Affective Disorders_. **13** (2): 119–30\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0165-0327(87)90017-6](https://doi.org/10.1016%2F0165-0327%2887%2990017-6). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2890677](https://pubmed.ncbi.nlm.nih.gov/2890677).\",\"description\":\"35. **^** Hayes, Peggy E.; Schulz, S. Charles (1987). [\\\"Beta-blockers in anxiety disorders\\\"](https://zenodo.org/record/1258347). _Journal of Affective Disorders_. **13** (2): 119–30\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0165-0327(87)90017-6](https://doi.org/10.1016%2F0165-0327%2887%2990017-6). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2890677](https://pubmed.ncbi.nlm.nih.gov/2890677).\",\"url\":\"https://zenodo.org/record/1258347\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** Jefferson, James W. (1974). \\\"Beta-Adrenergic Receptor Blocking Drugs in Psychiatry\\\". _Archives of General Psychiatry_. **31** (5): 681–91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/archpsyc.1974.01760170071012](https://doi.org/10.1001%2Farchpsyc.1974.01760170071012). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [4155284](https://pubmed.ncbi.nlm.nih.gov/4155284).\",\"description\":\"36. **^** Jefferson, James W. (1974). \\\"Beta-Adrenergic Receptor Blocking Drugs in Psychiatry\\\". _Archives of General Psychiatry_. **31** (5): 681–91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/archpsyc.1974.01760170071012](https://doi.org/10.1001%2Farchpsyc.1974.01760170071012). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [4155284](https://pubmed.ncbi.nlm.nih.gov/4155284).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Koola, M. M.; Varghese, S. P.; Fawcett, J. A. (2013). [\\\"High-dose prazosin for the treatment of post-traumatic stress disorder\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131). _Therapeutic Advances in Psychopharmacology_. **4** (1): 43–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/2045125313500982](https://doi.org/10.1177%2F2045125313500982). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3896131](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24490030](https://pubmed.ncbi.nlm.nih.gov/24490030).\",\"description\":\"37. **^** Koola, M. M.; Varghese, S. P.; Fawcett, J. A. (2013). [\\\"High-dose prazosin for the treatment of post-traumatic stress disorder\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131). _Therapeutic Advances in Psychopharmacology_. **4** (1): 43–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1177/2045125313500982](https://doi.org/10.1177%2F2045125313500982). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3896131](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24490030](https://pubmed.ncbi.nlm.nih.gov/24490030).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Hoehn-Saric, Rudolf; Merchant, A. F.; Keyser, M. L.; Smith, V. K. (1981). \\\"Effects of Clonidine on Anxiety Disorders\\\". _Archives of General Psychiatry_. **38** (11): 1278–82\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/archpsyc.1981.01780360094011](https://doi.org/10.1001%2Farchpsyc.1981.01780360094011). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7305609](https://pubmed.ncbi.nlm.nih.gov/7305609).\",\"description\":\"38. **^** Hoehn-Saric, Rudolf; Merchant, A. F.; Keyser, M. L.; Smith, V. K. (1981). \\\"Effects of Clonidine on Anxiety Disorders\\\". _Archives of General Psychiatry_. **38** (11): 1278–82\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/archpsyc.1981.01780360094011](https://doi.org/10.1001%2Farchpsyc.1981.01780360094011). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7305609](https://pubmed.ncbi.nlm.nih.gov/7305609).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** [_Annual Reports in Medicinal Chemistry, Volume 32 p. 319_](https://books.google.com/books?id=oJY8LrP_JysC\u0026q=%22Azapirone%22+%225-HT1A%22+%22receptor%22+%22Sediel%22\u0026pg=PA319)\",\"description\":\"39. **^** [_Annual Reports in Medicinal Chemistry, Volume 32 p. 319_](https://books.google.com/books?id=oJY8LrP_JysC\u0026q=%22Azapirone%22+%225-HT1A%22+%22receptor%22+%22Sediel%22\u0026pg=PA319)\",\"url\":\"https://books.google.com/books?id=oJY8LrP_JysC\u0026q=%22Azapirone%22+%225-HT1A%22+%22receptor%22+%22Sediel%22\u0026pg=PA319\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** DeMartinis, N.; Rynn, M.; Rickels, K.; Mandos, L. (February 2000). \\\"Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder\\\". _The Journal of Clinical Psychiatry_. **61** (2): 91–94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/jcp.v61n0203](https://doi.org/10.4088%2Fjcp.v61n0203). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0160-6689](https://search.worldcat.org/issn/0160-6689). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10732655](https://pubmed.ncbi.nlm.nih.gov/10732655).\",\"description\":\"40. **^** DeMartinis, N.; Rynn, M.; Rickels, K.; Mandos, L. (February 2000). \\\"Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder\\\". _The Journal of Clinical Psychiatry_. **61** (2): 91–94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/jcp.v61n0203](https://doi.org/10.4088%2Fjcp.v61n0203). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0160-6689](https://search.worldcat.org/issn/0160-6689). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10732655](https://pubmed.ncbi.nlm.nih.gov/10732655).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"** Bandelow, Borwin; Wedekind, Dirk; Leon, Teresa (2014). \\\"Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention\\\". _Expert Review of Neurotherapeutics_. **7** (7): 769–81\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1586/14737175.7.7.769](https://doi.org/10.1586%2F14737175.7.7.769). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17610384](https://pubmed.ncbi.nlm.nih.gov/17610384). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6229344](https://api.semanticscholar.org/CorpusID:6229344).\",\"description\":\"41. **^** Bandelow, Borwin; Wedekind, Dirk; Leon, Teresa (2014). \\\"Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention\\\". _Expert Review of Neurotherapeutics_. **7** (7): 769–81\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1586/14737175.7.7.769](https://doi.org/10.1586%2F14737175.7.7.769). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17610384](https://pubmed.ncbi.nlm.nih.gov/17610384). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6229344](https://api.semanticscholar.org/CorpusID:6229344).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"** Owen, R.T. (2007). \\\"Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety\\\". _Drugs of Today_. **43** (9): 601–10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1358/dot.2007.43.9.1133188](https://doi.org/10.1358%2Fdot.2007.43.9.1133188). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17940637](https://pubmed.ncbi.nlm.nih.gov/17940637).\",\"description\":\"42. **^** Owen, R.T. (2007). \\\"Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety\\\". _Drugs of Today_. **43** (9): 601–10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1358/dot.2007.43.9.1133188](https://doi.org/10.1358%2Fdot.2007.43.9.1133188). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17940637](https://pubmed.ncbi.nlm.nih.gov/17940637).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** Llorca, Pierre-Michel; Spadone, Christian; Sol, Olivier; Danniau, Anne; Bougerol, Thierry; Corruble, Emmanuelle; Faruch, Michel; Macher, Jean-Paul; Sermet, Eric; Servant, Dominique (2002). \\\"Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder\\\". _The Journal of Clinical Psychiatry_. **63** (11): 1020–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/JCP.v63n1112](https://doi.org/10.4088%2FJCP.v63n1112). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12444816](https://pubmed.ncbi.nlm.nih.gov/12444816).\",\"description\":\"43. **^** Llorca, Pierre-Michel; Spadone, Christian; Sol, Olivier; Danniau, Anne; Bougerol, Thierry; Corruble, Emmanuelle; Faruch, Michel; Macher, Jean-Paul; Sermet, Eric; Servant, Dominique (2002). \\\"Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder\\\". _The Journal of Clinical Psychiatry_. **63** (11): 1020–7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4088/JCP.v63n1112](https://doi.org/10.4088%2FJCP.v63n1112). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12444816](https://pubmed.ncbi.nlm.nih.gov/12444816).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"_**a**_ _**b**_ Lapin, Izyaslav (2001). [\\\"Phenibut (β-Phenyl-GABA): A Tranquilizer and Nootropic Drug\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145). _CNS Drug Reviews_. **7** (4): 471–481\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1527-3458.2001.tb00211.x](https://doi.org/10.1111%2Fj.1527-3458.2001.tb00211.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-3458](https://search.worldcat.org/issn/1527-3458). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6494145](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11830761](https://pubmed.ncbi.nlm.nih.gov/11830761).\",\"description\":\"44. ^ _**a**_ _**b**_ Lapin, Izyaslav (2001). [\\\"Phenibut (β-Phenyl-GABA): A Tranquilizer and Nootropic Drug\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145). _CNS Drug Reviews_. **7** (4): 471–481\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1527-3458.2001.tb00211.x](https://doi.org/10.1111%2Fj.1527-3458.2001.tb00211.x). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-3458](https://search.worldcat.org/issn/1527-3458). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6494145](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11830761](https://pubmed.ncbi.nlm.nih.gov/11830761).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494145\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"** журнал», Издание для практикующих врачей «Русский медицинский. [\\\"Феномен аминофенилмасляной кислоты\\\"](http://www.rmj.ru/articles/nevrologiya/Fenomen_aminofenilmaslyanoy_kisloty/). _www.rmj.ru_. Retrieved 19 December 2018.\",\"description\":\"45. **^** журнал», Издание для практикующих врачей «Русский медицинский. [\\\"Феномен аминофенилмасляной кислоты\\\"](http://www.rmj.ru/articles/nevrologiya/Fenomen_aminofenilmaslyanoy_kisloty/). _www.rmj.ru_. Retrieved 19 December 2018.\",\"url\":\"http://www.rmj.ru/articles/nevrologiya/Fenomen_aminofenilmaslyanoy_kisloty/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"** Zvejniece, Liga; Vavers, Edijs; Svalbe, Baiba; Veinberg, Grigory; Rizhanova, Kristina; Liepins, Vilnis; Kalvinsh, Ivars; Dambrova, Maija (1 October 2015). \\\"R-phenibut binds to the α2–δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects\\\". _Pharmacology Biochemistry and Behavior_. **137** : 23–29\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pbb.2015.07.014](https://doi.org/10.1016%2Fj.pbb.2015.07.014). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0091-3057](https://search.worldcat.org/issn/0091-3057). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26234470](https://pubmed.ncbi.nlm.nih.gov/26234470). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [42606053](https://api.semanticscholar.org/CorpusID:42606053).\",\"description\":\"46. **^** Zvejniece, Liga; Vavers, Edijs; Svalbe, Baiba; Veinberg, Grigory; Rizhanova, Kristina; Liepins, Vilnis; Kalvinsh, Ivars; Dambrova, Maija (1 October 2015). \\\"R-phenibut binds to the α2–δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects\\\". _Pharmacology Biochemistry and Behavior_. **137** : 23–29\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pbb.2015.07.014](https://doi.org/10.1016%2Fj.pbb.2015.07.014). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0091-3057](https://search.worldcat.org/issn/0091-3057). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26234470](https://pubmed.ncbi.nlm.nih.gov/26234470). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [42606053](https://api.semanticscholar.org/CorpusID:42606053).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"** Owen, David R.; Wood, David M.; Archer, John R. H.; Dargan, Paul I. (2016). \\\"Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity\\\". _Drug and Alcohol Review_. **35** (5): 591–596\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/dar.12356](https://doi.org/10.1111%2Fdar.12356). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10044/1/30073](https://hdl.handle.net/10044%2F1%2F30073). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1465-3362](https://search.worldcat.org/issn/1465-3362). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26693960](https://pubmed.ncbi.nlm.nih.gov/26693960).\",\"description\":\"47. **^** Owen, David R.; Wood, David M.; Archer, John R. H.; Dargan, Paul I. (2016). \\\"Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity\\\". _Drug and Alcohol Review_. **35** (5): 591–596\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/dar.12356](https://doi.org/10.1111%2Fdar.12356). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10044/1/30073](https://hdl.handle.net/10044%2F1%2F30073). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1465-3362](https://search.worldcat.org/issn/1465-3362). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26693960](https://pubmed.ncbi.nlm.nih.gov/26693960).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"** Cohen, Pieter A.; Ellison, Ross R.; Travis, John C.; Gaufberg, Slava V.; Gerona, Roy (22 September 2021). \\\"Quantity of phenibut in dietary supplements before and after FDA warnings\\\". _Clinical Toxicology_. **60** (4): 486–488\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/15563650.2021.1973020](https://doi.org/10.1080%2F15563650.2021.1973020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34550038](https://pubmed.ncbi.nlm.nih.gov/34550038). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [237594860](https://api.semanticscholar.org/CorpusID:237594860).\",\"description\":\"48. **^** Cohen, Pieter A.; Ellison, Ross R.; Travis, John C.; Gaufberg, Slava V.; Gerona, Roy (22 September 2021). \\\"Quantity of phenibut in dietary supplements before and after FDA warnings\\\". _Clinical Toxicology_. **60** (4): 486–488\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/15563650.2021.1973020](https://doi.org/10.1080%2F15563650.2021.1973020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34550038](https://pubmed.ncbi.nlm.nih.gov/34550038). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [237594860](https://api.semanticscholar.org/CorpusID:237594860).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"** [\\\"Adaptol. Summary of Product Characteristics\\\"](https://web.archive.org/web/20151203130342/http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf) (PDF). Archived from [the original](http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf) (PDF) on 3 December 2015. Retrieved 24 July 2015.\",\"description\":\"49. **^** [\\\"Adaptol. Summary of Product Characteristics\\\"](https://web.archive.org/web/20151203130342/http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf) (PDF). Archived from [the original](http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf) (PDF) on 3 December 2015. Retrieved 24 July 2015.\",\"url\":\"https://web.archive.org/web/20151203130342/http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"** Val'dman AV, Zaikonnikova IV, Kozlovskaia MM, Zimakova IE (1980). \\\"[Characteristics of the psychotropic spectrum of action of mebicar]\\\". _Biulleten' Eksperimental'noĭ Biologii I Meditsiny_ (in Russian). **89** (5): 568–70\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6104993](https://pubmed.ncbi.nlm.nih.gov/6104993).\",\"description\":\"50. **^** Val'dman AV, Zaikonnikova IV, Kozlovskaia MM, Zimakova IE (1980). \\\"[Characteristics of the psychotropic spectrum of action of mebicar]\\\". _Biulleten' Eksperimental'noĭ Biologii I Meditsiny_ (in Russian). **89** (5): 568–70\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6104993](https://pubmed.ncbi.nlm.nih.gov/6104993).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"** Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). \\\"Clinical study of the selective anxiolytic agent afobazol\\\". _Eksperimental'naia i Klinicheskaia Farmakologiia_. **64** (2): 15–9\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11548440](https://pubmed.ncbi.nlm.nih.gov/11548440).\",\"description\":\"51. **^** Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). \\\"Clinical study of the selective anxiolytic agent afobazol\\\". _Eksperimental'naia i Klinicheskaia Farmakologiia_. **64** (2): 15–9\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11548440](https://pubmed.ncbi.nlm.nih.gov/11548440).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"** Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). \\\"Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon\\\". _Eksperimental'naia i Klinicheskaia Farmakologiia_. **68** (1): 20–4\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15786959](https://pubmed.ncbi.nlm.nih.gov/15786959).\",\"description\":\"52. **^** Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). \\\"Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon\\\". _Eksperimental'naia i Klinicheskaia Farmakologiia_. **68** (1): 20–4\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15786959](https://pubmed.ncbi.nlm.nih.gov/15786959).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"** Vakhitova IuV, Iamidanov RS, Seredinin SB (2004). \\\"[Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]\\\". _Eksp Klin Farmakol_ (in Russian). **67** (4): 7–11\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15500036](https://pubmed.ncbi.nlm.nih.gov/15500036).\",\"description\":\"53. **^** Vakhitova IuV, Iamidanov RS, Seredinin SB (2004). \\\"[Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]\\\". _Eksp Klin Farmakol_ (in Russian). **67** (4): 7–11\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15500036](https://pubmed.ncbi.nlm.nih.gov/15500036).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"** Vakhitova, Yu. V.; Yamidanov, R. S.; Vakhitov, V. A.; Seredenin, S. B. (2005). \\\"The effect of ladasten on gene expression in the rat brain\\\". _Doklady Biochemistry and Biophysics_. **401** (1–6): 150–153\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10628-005-0057-z](https://doi.org/10.1007%2Fs10628-005-0057-z). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1607-6729](https://search.worldcat.org/issn/1607-6729). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15999825](https://pubmed.ncbi.nlm.nih.gov/15999825). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [28048257](https://api.semanticscholar.org/CorpusID:28048257).\",\"description\":\"54. **^** Vakhitova, Yu. V.; Yamidanov, R. S.; Vakhitov, V. A.; Seredenin, S. B. (2005). \\\"The effect of ladasten on gene expression in the rat brain\\\". _Doklady Biochemistry and Biophysics_. **401** (1–6): 150–153\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10628-005-0057-z](https://doi.org/10.1007%2Fs10628-005-0057-z). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1607-6729](https://search.worldcat.org/issn/1607-6729). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15999825](https://pubmed.ncbi.nlm.nih.gov/15999825). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [28048257](https://api.semanticscholar.org/CorpusID:28048257).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"** Volchegorskii, I. A.; Miroshnichenko, I. Yu.; Rassokhina, L. M.; Faizullin, R. M.; Malkin, M. P.; Pryakhina, K. E.; Kalugina, A. V. (2015). \\\"Comparative Analysis of the Anxiolytic Effects of 3-Hydroxypyridine and Succinic Acid Derivatives\\\". _Bulletin of Experimental Biology and Medicine_. **158** (6): 756–61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10517-015-2855-3](https://doi.org/10.1007%2Fs10517-015-2855-3). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25894772](https://pubmed.ncbi.nlm.nih.gov/25894772). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6052275](https://api.semanticscholar.org/CorpusID:6052275).\",\"description\":\"55. **^** Volchegorskii, I. A.; Miroshnichenko, I. Yu.; Rassokhina, L. M.; Faizullin, R. M.; Malkin, M. P.; Pryakhina, K. E.; Kalugina, A. V. (2015). \\\"Comparative Analysis of the Anxiolytic Effects of 3-Hydroxypyridine and Succinic Acid Derivatives\\\". _Bulletin of Experimental Biology and Medicine_. **158** (6): 756–61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10517-015-2855-3](https://doi.org/10.1007%2Fs10517-015-2855-3). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25894772](https://pubmed.ncbi.nlm.nih.gov/25894772). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6052275](https://api.semanticscholar.org/CorpusID:6052275).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"** Rumyantseva, S. A.; Fedin, A. I.; Sokhova, O. N. (2012). \\\"Antioxidant Treatment of Ischemic Brain Lesions\\\". _Neuroscience and Behavioral Physiology_. **42** (8): 842–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s11055-012-9646-3](https://doi.org/10.1007%2Fs11055-012-9646-3). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [39971165](https://api.semanticscholar.org/CorpusID:39971165). [INIST](Institut_de_l'information_scientifique_et_technique \\\"Institut de l'information scientifique et technique\\\") [26388033](https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail\u0026idt=26388033).\",\"description\":\"56. **^** Rumyantseva, S. A.; Fedin, A. I.; Sokhova, O. N. (2012). \\\"Antioxidant Treatment of Ischemic Brain Lesions\\\". _Neuroscience and Behavioral Physiology_. **42** (8): 842–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s11055-012-9646-3](https://doi.org/10.1007%2Fs11055-012-9646-3). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [39971165](https://api.semanticscholar.org/CorpusID:39971165). [INIST](Institut_de_l'information_scientifique_et_technique \\\"Institut de l'information scientifique et technique\\\") [26388033](https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail\u0026idt=26388033).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"** [\\\"Validol\\\"](http://encyclopedia2.thefreedictionary.com/Validol). _The Great Soviet Encyclopedia_.\",\"description\":\"57. **^** [\\\"Validol\\\"](http://encyclopedia2.thefreedictionary.com/Validol). _The Great Soviet Encyclopedia_.\",\"url\":\"http://encyclopedia2.thefreedictionary.com/Validol\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"** [\\\"Farmak Product Information - Validol\\\"](https://web.archive.org/web/20131219200018/http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf) (PDF). Archived from [the original](http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf) (PDF) on 19 December 2013. Retrieved 9 April 2013.\",\"description\":\"58. **^** [\\\"Farmak Product Information - Validol\\\"](https://web.archive.org/web/20131219200018/http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf) (PDF). Archived from [the original](http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf) (PDF) on 19 December 2013. Retrieved 9 April 2013.\",\"url\":\"https://web.archive.org/web/20131219200018/http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"** Malykh, Andrei G.; Sadaie, M. Reza (2010). \\\"Piracetam and Piracetam-Like Drugs\\\". _Drugs_. **70** (3): 287–312\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/11319230-000000000-00000](https://doi.org/10.2165%2F11319230-000000000-00000). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20166767](https://pubmed.ncbi.nlm.nih.gov/20166767). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [12176745](https://api.semanticscholar.org/CorpusID:12176745).\",\"description\":\"59. **^** Malykh, Andrei G.; Sadaie, M. Reza (2010). \\\"Piracetam and Piracetam-Like Drugs\\\". _Drugs_. **70** (3): 287–312\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2165/11319230-000000000-00000](https://doi.org/10.2165%2F11319230-000000000-00000). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20166767](https://pubmed.ncbi.nlm.nih.gov/20166767). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [12176745](https://api.semanticscholar.org/CorpusID:12176745).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"_**a**_ _**b**_ Skolnick P (November 2012). [\\\"Anxioselective anxiolytics: on a quest for the Holy Grail\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271). _Trends Pharmacol Sci_. **33** (11): 611–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.tips.2012.08.003](https://doi.org/10.1016%2Fj.tips.2012.08.003). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3482271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22981367](https://pubmed.ncbi.nlm.nih.gov/22981367).\",\"description\":\"60. ^ _**a**_ _**b**_ Skolnick P (November 2012). [\\\"Anxioselective anxiolytics: on a quest for the Holy Grail\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271). _Trends Pharmacol Sci_. **33** (11): 611–20\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.tips.2012.08.003](https://doi.org/10.1016%2Fj.tips.2012.08.003). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3482271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22981367](https://pubmed.ncbi.nlm.nih.gov/22981367).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482271\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"_**a**_ _**b**_ Nuss, Philippe; Ferreri, Florian; Bourin, Michel (2019). [\\\"An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action (Review)\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018). _Neuropsychiatric Disease and Treatment_. **15** : 1781–1795\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2147/ndt.s200568](https://doi.org/10.2147%2Fndt.s200568). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1178-2021](https://search.worldcat.org/issn/1178-2021). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6615018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31308671](https://pubmed.ncbi.nlm.nih.gov/31308671).\",\"description\":\"61. ^ _**a**_ _**b**_ Nuss, Philippe; Ferreri, Florian; Bourin, Michel (2019). [\\\"An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action (Review)\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018). _Neuropsychiatric Disease and Treatment_. **15** : 1781–1795\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.2147/ndt.s200568](https://doi.org/10.2147%2Fndt.s200568). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1178-2021](https://search.worldcat.org/issn/1178-2021). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6615018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31308671](https://pubmed.ncbi.nlm.nih.gov/31308671).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"** Gilman, J. M.; Ramchandani, V. A.; Davis, M. B.; Bjork, J. M.; Hommer, D. W. (2008). [\\\"Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732). _Journal of Neuroscience_. **28** (18): 4583–91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.0086-08.2008](https://doi.org/10.1523%2FJNEUROSCI.0086-08.2008). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2730732](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18448634](https://pubmed.ncbi.nlm.nih.gov/18448634).\",\"description\":\"62. **^** Gilman, J. M.; Ramchandani, V. A.; Davis, M. B.; Bjork, J. M.; Hommer, D. W. (2008). [\\\"Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732). _Journal of Neuroscience_. **28** (18): 4583–91\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.0086-08.2008](https://doi.org/10.1523%2FJNEUROSCI.0086-08.2008). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2730732](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18448634](https://pubmed.ncbi.nlm.nih.gov/18448634).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730732\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"** Shearer, Steven L. (2007). \\\"Recent Advances in the Understanding and Treatment of Anxiety Disorders\\\". _Primary Care: Clinics in Office Practice_. **34** (3): 475–504, v–vi. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pop.2007.05.002](https://doi.org/10.1016%2Fj.pop.2007.05.002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17868756](https://pubmed.ncbi.nlm.nih.gov/17868756).\",\"description\":\"63. **^** Shearer, Steven L. (2007). \\\"Recent Advances in the Understanding and Treatment of Anxiety Disorders\\\". _Primary Care: Clinics in Office Practice_. **34** (3): 475–504, v–vi. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pop.2007.05.002](https://doi.org/10.1016%2Fj.pop.2007.05.002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17868756](https://pubmed.ncbi.nlm.nih.gov/17868756).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"** Pull, Charles B (2007). \\\"Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders\\\". _Current Opinion in Psychiatry_. **20** (1): 30–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/YCO.0b013e3280115e52](https://doi.org/10.1097%2FYCO.0b013e3280115e52). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17143079](https://pubmed.ncbi.nlm.nih.gov/17143079). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43737803](https://api.semanticscholar.org/CorpusID:43737803).\",\"description\":\"64. **^** Pull, Charles B (2007). \\\"Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders\\\". _Current Opinion in Psychiatry_. **20** (1): 30–5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/YCO.0b013e3280115e52](https://doi.org/10.1097%2FYCO.0b013e3280115e52). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17143079](https://pubmed.ncbi.nlm.nih.gov/17143079). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43737803](https://api.semanticscholar.org/CorpusID:43737803).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"** CMA \u0026 AMA Home medical guides 2012 \u0026 2014\",\"description\":\"65. **^** CMA \u0026 AMA Home medical guides 2012 \u0026 2014\",\"url\":\"\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"a medication or other intervention that reduces anxiety.\\\"\",\"explanation\":\"The term \\\"anxiolytic\\\" specifically denotes a class of pharmacological agents (medications or drugs) that reduce anxiety, not broader interventions such as psychotherapy or lifestyle changes. Including \\\"other intervention\\\" inaccurately expands the definition beyond standard medical and pharmacological usage, potentially misleading readers on the scope of the term.\",\"fixedText\":\"Revise to: \\\"a medication that reduces anxiety.\\\" This aligns with authoritative definitions focusing on pharmacological agents.\",\"evidenceSource\":\"[](https://my.clevelandclinic.org/health/treatments/24776-anxiolytics)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"also **antipanic** or **anti-anxiety agent**)[1]\",\"explanation\":\"Reference [1] is from Dorland's Medical Dictionary defining \\\"antianxiety agent,\\\" but does not explicitly support \\\"antipanic\\\" as a synonym. Standard sources confirm \\\"anti-anxiety agent\\\" but \\\"antipanic\\\" is less common and not directly tied to this ref, risking unsupported claim.\",\"fixedText\":\"Remove \\\"antipanic\\\" from synonyms or cite a source that supports it; retain \\\"anti-anxiety agent\\\" with [1].\",\"evidenceSource\":\"Existing ref #1\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"[Post-traumatic stress disorder (PTSD)](Post-traumatic_stress_disorder \\\"Post-traumatic stress disorder\\\") | PTSDs develop due to experience of severe trauma or life-threatening events. Specific symptoms include flashbacks to traumatic events triggered during similar situations, as well as avoidance of these situations. The fear of re-experiencing the event is also associated with feelings of helplessness or horror.   [Obsessive–compulsive disorder (OCD)](Obsessive%E2%80%93compulsive_disorder \\\"Obsessive–compulsive disorder\\\") | Person with OCD would experience compulsive impulses of removing an obsession.\\\"\",\"explanation\":\"In DSM-5, the standard classification system, PTSD is categorized under Trauma- and Stressor-Related Disorders, and OCD under Obsessive-Compulsive and Related Disorders, not Anxiety Disorders. Including them misstates the scope of anxiety disorders.\",\"fixedText\":\"Remove PTSD and OCD from the classification table. Replace with accurate anxiety disorders such as Agoraphobia and Separation Anxiety Disorder to maintain six types if desired, or adjust to \\\"common types\\\" without specifying number.\",\"evidenceSource\":\"[](https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Anxiety disorders are classified using six possible clinical assessments:[2]\\\"\",\"explanation\":\"The cited reference [2] is a clinical pharmacy textbook that likely follows standard classifications like DSM-5 but does not specify these exact six (including misclassified PTSD and OCD) as \\\"clinical assessments.\\\" The term \\\"clinical assessments\\\" is also imprecise; anxiety disorders are classified by diagnostic criteria in manuals like DSM-5.\",\"fixedText\":\"Rephrase to \\\"Common types of anxiety disorders include:\\\" and cite an authoritative source on DSM-5 classifications, such as the American Psychiatric Association.\",\"evidenceSource\":\"[2]; [](https://www.ncbi.nlm.nih.gov/books/NBK519704/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"[Social phobia](Social_Phobia \\\"Social Phobia\\\") | This refers to the fear of staging in social situations\\\"\",\"explanation\":\"The term \\\"social phobia\\\" is outdated; DSM-5 uses \\\"social anxiety disorder.\\\" The description has a likely typo (\\\"staging\\\" instead of \\\"engaging\\\"). Current classifications should use updated terminology as of DSM-5 (2013).\",\"fixedText\":\"Update to \\\"Social anxiety disorder\\\" and correct phrasing to \\\"engaging in social situations.\\\"\",\"evidenceSource\":\"[](https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of diagnostic framework.\",\"explanation\":\"The section describes classifications without referencing the standard diagnostic manual (e.g., DSM-5 or ICD-11), leading to knowledge gap on how these are formally defined, which is essential for accuracy in a medical context.\",\"fixedText\":\"Add reference to DSM-5 as the basis for classification.\",\"evidenceSource\":\"[](https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The etiology of anxiety disorder remains unknown.\",\"explanation\":\"The etiology is not unknown but multifactorial, involving interactions of genetic, environmental, biological, and psychological factors, as established in medical literature; presenting it as entirely unknown misrepresents the current understanding and could mislead on the nature of the disorders.\",\"fixedText\":\"Rephrase to: \\\"The etiology of anxiety disorders is multifactorial and involves an interaction of genetic vulnerability with environmental stressors.\\\"\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK470361/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"There are several contributing factors that are still yet to be proved to cause anxiety disorders.[2]\",\"explanation\":\"The cited source is a clinical pharmacy textbook likely discussing established risk factors in the context of treatment, not unproven causes; many listed factors (e.g., substance-induced anxiety, medical conditions) are recognized risk factors, not speculative, making the claim unsupported and inaccurate.\",\"fixedText\":\"Rephrase to describe established risk factors and retain [2] only if it supports specific factors; supplement with authoritative sources for completeness.\",\"evidenceSource\":\"[2]; [](https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"These factors include childhood anxiety, drug induction by central stimulant drugs, metabolic diseases or having depressive disorder.\",\"explanation\":\"The list is incomplete, omitting major etiological components like genetic predisposition, trauma, and environmental stress; \\\"having depressive disorder\\\" implies direct causation rather than shared risk or comorbidity; this creates knowledge gaps on primary factors, reducing the section's informativeness and accuracy in an encyclopedic context.\",\"fixedText\":\"Add key missing factors (e.g., genetics, trauma) and rephrase listed ones for precision (e.g., \\\"history of childhood anxiety\\\" instead of \\\"childhood anxiety\\\"; \\\"comorbid depression\\\" instead of causation).\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK470361/); [](https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The entire section focuses only on the history of antidepressants used for anxiety, omitting earlier anxiolytics.\",\"explanation\":\"The history section of an article on anxiolytics should cover the development of classical anxiolytics like barbiturates (early 1900s) and benzodiazepines (1960s), which were primary treatments before antidepressants were used off-label for anxiety. This creates a significant knowledge gap, misrepresenting the scope of anxiolytic history.\",\"fixedText\":\"Add introductory paragraphs on early anxiolytics, including barbiturates and benzodiazepines, before discussing antidepressants.\",\"evidenceSource\":\"[](https://www.benzoinfo.com/a-brief-history-of-benzodiazepines/); [](https://journals.sagepub.com/doi/pdf/10.1177/070674370505000702)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"The majority of TCAs exert greater effect on norepinephrine, which leads to side effects like drowsiness and memory loss.\\\"\",\"explanation\":\"Drowsiness is primarily caused by antihistaminergic (H1 receptor blockade) properties of TCAs, and memory loss by anticholinergic effects, not by norepinephrine reuptake inhibition. Attributing these side effects to NE effects is mechanistically incorrect.\",\"fixedText\":\"Revise to accurately attribute side effects to anticholinergic and antihistaminergic properties, removing the link to norepinephrine inhibition.\",\"evidenceSource\":\"[8]; [](https://www.ncbi.nlm.nih.gov/books/NBK557791/); [](https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"In order to be more effective on serotonin agonism\\\"\",\"explanation\":\"SSRIs do not directly agonize serotonin receptors; they inhibit serotonin reuptake, increasing synaptic serotonin levels that then act on postsynaptic receptors. \\\"Agonism\\\" implies direct receptor activation, which is incorrect for SSRIs.\",\"fixedText\":\"Change to \\\"more selective for serotonin reuptake inhibition\\\" or similar, avoiding \\\"agonism.\\\"\",\"evidenceSource\":\"[9]; [](https://www.ncbi.nlm.nih.gov/books/NBK554406/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"SNRIs can target serotonin and norepinephrine transporters while avoiding imposing significant effects on other adrenergic (α1, α2, and β), histamine (H1), muscarinic, dopamine, or postsynaptic serotonin receptors.[9]\\\"\",\"explanation\":\"Citation [9] is a StatPearls article on Selective Serotonin Reuptake Inhibitors (SSRIs), not SNRIs. The source does not support claims about SNRIs.\",\"fixedText\":\"Replace [9] with an appropriate citation for SNRIs, such as a review on their pharmacology.\",\"evidenceSource\":\"[9]; [](https://www.ncbi.nlm.nih.gov/books/NBK554406/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"However the neurotransmitter level of patients with anxiety disorders is usually low or the patients’ nerve fibers are insensitive to the neurotransmitters.\",\"explanation\":\"The claim oversimplifies the monoamine hypothesis, which posits dysregulation rather than definitively low serotonin/norepinephrine levels in anxiety disorders. Evidence shows mixed findings: some studies indicate low central serotonin transporter availability, but others suggest higher serotonin in certain anxiety types or a modulatory role, not uniform deficiency. This misstates the mechanism, potentially misleading on pathophysiology.\",\"fixedText\":\"Rephrase to: While the exact mechanisms are not fully understood, SSRIs and SNRIs are thought to exert anxiolytic effects by increasing synaptic levels of serotonin (and norepinephrine for SNRIs), leading to adaptive changes such as downregulation of presynaptic autoreceptors over time.\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK554406/); [](https://chandramd.com/anxiety-its-not-just-serotonin/); [](https://pubmed.ncbi.nlm.nih.gov/18268503/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"The nerve fibers will inhibit further production of neurotransmitters upon the increase. However the prolonged increase will eventually desensitize the nerve about the change in level.\",\"explanation\":\"This inaccurately describes autoregulation. Acute SSRI administration activates presynaptic 5-HT1A autoreceptors, initially reducing serotonin release despite reuptake inhibition. Therapeutic effects emerge after weeks due to desensitization/downregulation of these autoreceptors, allowing sustained increase in serotonin transmission, and postsynaptic adaptations. The phrasing reverses the sequence and uses vague terms like \\\"desensitize the nerve about the change.\\\"\",\"fixedText\":\"Clarify: Initially, the increase activates inhibitory autoreceptors, limiting serotonin release. Over 4-6 weeks, desensitization of these autoreceptors and other adaptations enhance serotonergic signaling, contributing to anxiolytic effects.\",\"evidenceSource\":\"[](https://pubmed.ncbi.nlm.nih.gov/10333979/); [](https://www.ncbi.nlm.nih.gov/books/NBK554406/)\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"[10] (for SSRIs/SNRIs mechanism)\",\"explanation\":\"\",\"fixedText\":\"\",\"evidenceSource\":\"\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"N/A\",\"explanation\":\"The section omits key adaptive mechanisms (e.g., 5-HT1A autoreceptor desensitization) central to delayed therapeutic onset in anxiety treatment, reducing completeness for a mechanism-focused section.\",\"fixedText\":\"Add brief mention of autoreceptor desensitization and postsynaptic changes for accuracy.\",\"evidenceSource\":\"[](https://pubmed.ncbi.nlm.nih.gov/10333979/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Safety/Health Risk\",\"problematicText\":\"\\\"Acute angle closure glaucoma\\\" listed under common side effects for Citalopram in SSRI table\",\"explanation\":\"Acute angle-closure glaucoma is a rare risk associated with SSRIs like citalopram, primarily in predisposed patients or overdose, not a common side effect. Listing it as \\\"common\\\" misleads on prevalence and could cause unnecessary alarm or oversight of actual common effects like nausea or dry mouth.\",\"fixedText\":\"Remove \\\"Acute angle closure glaucoma\\\" from the list of common side effects for Citalopram.\",\"evidenceSource\":\"Web search results from Mayo Clinic and Drugs.com confirm it as a precaution, not common (incidence \u0026lt;1%).\"},{\"criticality\":\"Critical\",\"issueType\":\"Safety/Health Risk\",\"problematicText\":\"\\\"Anxiety\\\" listed under common side effects for Clomipramine in TCA table\",\"explanation\":\"Clomipramine is used to treat anxiety disorders (e.g., OCD, phobias); listing \\\"anxiety\\\" as a common side effect is inaccurate and contradictory, as common effects include dry mouth, constipation, and drowsiness. This could confuse efficacy vs. adverse effects.\",\"fixedText\":\"Remove \\\"Anxiety\\\" from the list of common side effects for Clomipramine; add standard common effects if needed for accuracy.\",\"evidenceSource\":\"Drugs.com and Cleveland Clinic list no anxiety as common; instead, sedation and anticholinergic effects.\"},{\"criticality\":\"Critical\",\"issueType\":\"Safety/Health Risk\",\"problematicText\":\"\\\"Insomnia\\\" listed under common side effects for Alprazolam in Benzodiazepines table\",\"explanation\":\"Alprazolam is sedating and used for anxiety/insomnia; insomnia is not a common side effect but may occur as rebound upon discontinuation. Common effects include drowsiness and coordination issues. Mislisting could mislead on drug profile.\",\"fixedText\":\"Remove \\\"Insomnia\\\" from the list of common side effects for Alprazolam.\",\"evidenceSource\":\"Mayo Clinic and Drugs.com confirm common effects as drowsiness, dizziness; insomnia rare or rebound.\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"SSRI and TCA tables list some rare or unverified effects as \\\"Common side effect\\\" (e.g., hypersalivation for Citalopram, aggression for Clomipramine)\",\"explanation\":\"The tables misrepresent prevalence by labeling rare effects as common without sourcing, potentially altering clinical understanding of risks. Tables should only include verified common effects (\u0026gt;1-10% incidence).\",\"fixedText\":\"Revise tables to include only verified common side effects; remove or reclassify rare ones. Add citations where possible.\",\"evidenceSource\":\"Standard sources (e.g., Drugs.com, Mayo Clinic) show hypersalivation and aggression as rare (\u0026lt;1%) or not listed for these drugs.\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"TCAs may cause drug poisoning in patients with hypotension, cardiovascular diseases and arrhythmias.\\\"\",\"explanation\":\"Wording implies TCAs routinely cause poisoning; actually, they are contraindicated in these conditions due to risk of exacerbation or toxicity in overdose/normal use. Misstatement could confuse contraindications with causation.\",\"fixedText\":\"Rephrase to: \\\"TCAs are contraindicated in patients with hypotension, cardiovascular diseases, and arrhythmias due to risk of toxicity and exacerbation.\\\"\",\"evidenceSource\":\"Ref [27] discusses TCA overdose toxicity; standard guidelines (e.g., StatPearls [8]) note contraindications in CV disease.\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No mention of current guidelines (as of 2025) confirming SSRIs/SNRIs as first-line for most anxiety disorders.\",\"explanation\":\"Section claims SSRIs first-line [17], but lacks update to reflect ongoing status per recent guidelines, potentially outdated amid evolving evidence.\",\"fixedText\":\"Add: \\\"As of 2025, SSRIs remain first-line per major guidelines (e.g., APA, NICE).\\\" with new citation.\",\"evidenceSource\":\"APA and NICE guidelines (2024-2025) affirm SSRIs/SNRIs first-line for GAD, panic, etc.\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"research has not found a benefit of combined pharmacotherapy and psychotherapy versus monotherapy.\\\"[64]\",\"explanation\":\"The cited 2007 review states little benefit, but more recent meta-analyses (e.g., 2021 review in Focus journal) indicate combined CBT and benzodiazepines has greater effect size than CBT alone for anxiety disorders. Presenting this as current consensus is misleading given advancements since 2007.\",\"fixedText\":\"Update to reflect that while some older reviews found limited benefit, recent evidence supports combined treatment as potentially superior, especially for severe cases; cite recent source.\",\"evidenceSource\":\"[](https://psychiatryonline.org/doi/full/10.1176/appi.focus.20200045)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"If CBT is found ineffective, both the Canadian and American medical associations then suggest the use of medication.[65]\\\"\",\"explanation\":\"Ref 65 (\\\"CMA \u0026 AMA Home medical guides 2012 \u0026 2014\\\") is vague, outdated (over 10 years old), and not an official guideline document from CMA (Canadian Medical Association) or AMA (American Medical Association). Current guidelines from CANMAT/CPA (Canada) and APA (US) recommend CBT first-line, with medication if ineffective or inaccessible, but AMA lacks specific anxiety guidelines.\",\"fixedText\":\"Replace citation with current authoritative sources (e.g., CANMAT 2014/2023 updates, APA 2009/2021 reviews); clarify associations to psychiatric ones if appropriate, or generalize to major guidelines.\",\"evidenceSource\":\"[](https://www.canmat.org/) [](https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section\",\"explanation\":\"The section lacks mention of other evidence-based non-medication alternatives like mindfulness-based stress reduction (MBSR), acceptance and commitment therapy (ACT), or lifestyle interventions (exercise, sleep hygiene), which are recommended in current guidelines for anxiety (as of 2024). This creates a knowledge gap in comprehensive alternatives.\",\"fixedText\":\"Add brief mention of additional psychotherapies and self-management strategies supported by recent guidelines.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001348/)\"}],\"slug\":\"Anxiolytic\",\"title\":\"Anxiolytic\",\"content\":\"$1f\",\"description\":\"Anxiolytic\\n\\nAn anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety.\",\"metadata\":{\"categories\":[\"anxiolytics\",\"anti-anxiety drug\",\"anti-anxiety medication\",\"minor tranquilizer\"],\"lastModified\":\"1761553399\",\"contentLength\":\"30630\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"295737\",\"recentViews\":\"295737\",\"dailyAvgViews\":9857.900390625,\"qualityScore\":1,\"lastViewed\":\"1761886653\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886654149,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Anxiolytic\"],\"queryHash\":\"[\\\"page\\\",\\\"Anxiolytic\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Anxiolytic\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"anxiolytics, anti-anxiety drug, anti-anxiety medication, minor tranquilizer\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Anxiolytic\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Anxiolytic\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Anxiolytic\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Anxiolytic\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.399Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Anxiolytic\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also anti-anxiety agent)[1] is a medication that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. Anxiety is a naturally occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZmJiMWYxYzAtZmQ2Mi00YjA3LTkzZGYtOGU2OGZlOWE3NmM0">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Anxiolytic\"}]}]\n"])</script></body></html>